[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 37312
1. Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L, Lahortiga I, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prósper F: Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer; 2006 Apr 15;118(8):1945-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia.
  • We have studied the role of promoter hypermethylation in the regulation of PARK2 and PACRG expression in different tumor cell lines and primary patient samples.
  • Abnormal methylation of the common promoter of PARK2 and PACRG was observed in 26% of patients with acute lymphoblastic leukemia and 20% of patients with chronic myelogenous leukemia (CML) in lymphoid blast crisis, but not in ovarian, breast, lung, neuroblastoma, astrocytoma or colon cancer cells.
  • In conclusion, our results demonstrate for the first time that the candidate tumor suppressor genes PARK2 and PACRG are epigenetically regulated in human leukemia, suggesting that abnormal methylation and regulation of PARK2 and PACRG may play a role in the pathogenesis and development of this hematological neoplasm.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proteins / physiology. Ubiquitin-Protein Ligases / biosynthesis

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287063.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / U01CA7629303
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Chaperones; 0 / PACRG protein, human; 0 / Proteins; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / parkin protein
  •  go-up   go-down


2. Colović N, Terzić T, Andelić B, Sretenović M, Mihaljević B, Lipkovski JM, Colović M: Nephrotic syndrome and acute renal failure in non-Hodgkin lymphoplasmacytic lymphoma. Med Oncol; 2008;25(4):458-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrotic syndrome and acute renal failure in non-Hodgkin lymphoplasmacytic lymphoma.
  • Two patients with lymphoplasmacytic lymphoma, and monoclonal proteins of IgM in one, and IgG and lambda light chains in the second patient, nephrotic syndrome and acute renal failure are reported.
  • A 58-year-old man previously treated for pre-B acute lymphoblastic leukemia, developed 3 years later nephrotic syndrome as a complication of lymphoplasmacytic lymphoma and high-paraprotein IgM kappa type.
  • The second patient is a 42-year-old female diagnosed with lymphoplasmacytic lymphoma and paraprotein IgG lambda type.
  • The course of the disease was fulminant with developing nephrotic syndrome and fatal acute renal failure.
  • [MeSH-major] Acute Kidney Injury / complications. Lymphoma, Non-Hodgkin / complications. Nephrotic Syndrome / complications. Waldenstrom Macroglobulinemia / complications

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1975 Apr;58(4):567-75 [804814.001]
  • [Cites] Am J Kidney Dis. 2001 Nov;38(5):1135-40 [11684573.001]
  • [Cites] Clin Exp Immunol. 1980 Aug;41(2):196-204 [6777101.001]
  • [Cites] N Engl J Med. 1970 Jul 16;283(3):123-9 [4987279.001]
  • [Cites] Annu Rev Med. 1989;40:53-60 [2499246.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):85-96 [14675039.001]
  • (PMID = 18214715.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


3. Perkins JL, Kunin-Batson AS, Youngren NM, Ness KK, Ulrich KJ, Hansen MJ, Petryk A, Steinberger J, Anderson FS, Baker KS: Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer; 2007 Dec;49(7):958-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age.
  • BACKGROUND: Hematopoeitic cell transplantation (HCT) in childhood has been associated with late complications including endocrine, neurocognitive, and cardiopulmonary abnormalities.
  • PROCEDURE: Eligible subjects underwent HCT for acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) at less than 3 years of age.
  • Dyslipidemias affect more than half of patients and may be associated with metabolic syndrome, placing patients at increased risk for early cardiovascular disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning
  • [MeSH-minor] Child, Preschool. Dyslipidemias / pathology. Female. Follow-Up Studies. Humans. Infant. Male. Metabolic Syndrome X / diagnosis. Quality of Life. Risk Factors. Survival Rate. Time. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation


Advertisement
4. Vijayakrishnan J, Sherborne AL, Sawangpanich R, Hongeng S, Houlston RS, Pakakasama S: Variation at 7p12.2 and 10q21.2 influences childhood acute lymphoblastic leukemia risk in the Thai population and may contribute to racial differences in leukemia incidence. Leuk Lymphoma; 2010 Oct;51(10):1870-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation at 7p12.2 and 10q21.2 influences childhood acute lymphoblastic leukemia risk in the Thai population and may contribute to racial differences in leukemia incidence.
  • Recent genome-wide association (GWA) studies of childhood acute lymphoblastic leukemia (ALL) have identified 7p12.2, 9p21.3, 10q21.2, and 14q11.2 SNPs that confer modest risks of ALL.
  • Consistent with findings in European populations, rs4132601 genotype was significantly associated with risk of ALL (odds ratio [OR] = 1.57, 95% confidence interval [CI]: 1.01-2.44; p = 0.04), and rs10821938 genotype was significantly associated with B-cell precursor ALL (OR = 0.73, 95% CI: 0.55-0.97; p = 0.03).
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Asian Continental Ancestry Group / genetics. Case-Control Studies. Child. European Continental Ancestry Group / genetics. Female. Gene Frequency. Genetic Predisposition to Disease / genetics. Genotype. Humans. Incidence. Linkage Disequilibrium. Male. Risk Factors. Thailand / epidemiology. Young Adult


5. Zeng Y, Ni X, Meng WT, Wen Q, Jia YQ: [Inhibitive effect of artesunate on human lymphoblastic leukemia/lymphoma cells]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov;40(6):1038-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhibitive effect of artesunate on human lymphoblastic leukemia/lymphoma cells].
  • OBJECTIVE: To test the effect of Artesunate (ART) on the proliferation of Raji cells, Jurkat cells and acute lymphoblastic leukemia (ALL) primary cells; to determine the synergistic antiproliferation effect between ART and Vincristine (VCR) or Cytarabine(Ara-C) on Raji and Jurkat cells; and to explore the mechanism of ART induced apoptosis of tumor cells in vitro.
  • METHODS: MTT assay was performed to detect the inhibition of proliferation of Raji, Jurkat, and ALL primary cells.
  • CONCLUSION: ART alone or combined with chemotherapy drugs could inhibit the proliferation of B/T lymphocytic tumor cell lines as well ALL primary cells in vitro, probably through the mechanism of apoptosis, which suggest that ART is likely to be a potential drug in the treatment of leukemia/lymphoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Artemisinins / pharmacology. Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Blood-Brain Barrier / drug effects. Cell Line, Tumor. Cytarabine / pharmacology. Drug Synergism. Humans. Jurkat Cells

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067115.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Artemisinins; 04079A1RDZ / Cytarabine; 60W3249T9M / artesunate
  •  go-up   go-down


6. Lisowska G, Namysłowski G, Hajduk A, Polok A, Tomaszewska R, Misiołek M: [Hearing evaluation in children during chemotherapy]. Pol Merkur Lekarski; 2005 Sep;19(111):340-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tonal audiometry, emission audiometry and DPOAEs were measured in 7 children with acute lymphoblastic leukemia (ALL).
  • [MeSH-minor] Adolescent. Audiometry. Audiometry, Pure-Tone. Child. Child, Preschool. Female. Humans. Male. Otoacoustic Emissions, Spontaneous / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Predictive Value of Tests. Sensitivity and Specificity. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358863.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. van Vlierberghe P, Meijerink JP, Lee C, Ferrando AA, Look AT, van Wering ER, Beverloo HB, Aster JC, Pieters R: A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia. Leukemia; 2006 Jul;20(7):1245-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia.
  • Over the last decade, genetic characterization of T-cell acute lymphoblastic leukemia (T-ALL) has led to the identification of a variety of chromosomal abnormalities.
  • Fluorescence in situ hybridization (FISH) analysis revealed that this 9q34 amplification was in fact a 9q34 duplication on one chromosome and could be identified in 17-39 percent of leukemic cells at diagnosis.
  • [MeSH-major] Chromosomes, Human, Pair 9. Gene Duplication. Leukemia-Lymphoma, Adult T-Cell / genetics


8. Clarke SA, Davies H, Jenney M, Glaser A, Eiser C: Parental communication and children's behaviour following diagnosis of childhood leukaemia. Psychooncology; 2005 Apr;14(4):274-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parental communication and children's behaviour following diagnosis of childhood leukaemia.
  • In this study 55 parents of children (36 boys and 19 girls, mean age = 7.33 years) newly diagnosed with acute lymphoblastic leukaemia (ALL) were interviewed about (i) the child's reactions and behaviour following diagnosis, (ii) their views about what to tell their child and (iii) factors influencing parents' communication with the child.
  • Most children showed behavioural and mood difficulties after diagnosis.
  • [MeSH-major] Communication. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Truth Disclosure

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 John Wiley & Sons, Ltd.
  • (PMID = 15386768.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Foster M: Sports dentistry--what's it all about? SADJ; 2009 Jun;64(5):198, 200-2, 204 passim
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CLINICAL RELEVANCE: The early diagnosis and management of dental conditions that affect athletes will ensure sound dental health is preserved for these high risk patients.
  • The clinician needs to be aware of a variety of dental conditions that can prevent significant dental trauma and acute manifestations at the time of competition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] Dent Update. 2009 Apr;36(3):135-8, 141-4 [19480101.001]
  • (PMID = 19725331.001).
  • [ISSN] 1029-4864
  • [Journal-full-title] SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging
  • [ISO-abbreviation] SADJ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


10. Griffioen M, Kessler JH, Borghi M, van Soest RA, van der Minne CE, Nouta J, van der Burg SH, Medema JP, Schrier PI, Falkenburg JH, Osanto S, Melief CJ: Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res; 2006 May 15;12(10):3130-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
  • PURPOSE: Preferentially expressed antigen on melanomas (PRAME) is an interesting antigen for T-cell therapy because it is frequently expressed in melanomas (95%) and other tumor types.
  • Moreover, due to its role in oncogenic transformation, PRAME-negative tumor cells are not expected to easily arise and escape from T-cell immunity.
  • The purpose of this study is to investigate the usefulness of PRAME as target for anticancer T-cell therapies.
  • EXPERIMENTAL DESIGN: HLA-A*0201-subtyped healthy individuals and advanced melanoma patients were screened for CD8+ T cells directed against previously identified HLA-A*0201-binding PRAME peptides by IFN-gamma enzyme-linked immunosorbent spot assays and tetramer staining.
  • PRAME-specific T-cell clones were isolated and tested for recognition of melanoma and acute lymphoid leukemia (ALL) cell lines.
  • PRA(100-108)-tetramer+ T-cell clones were shown to recognize and lyse HLA-A*0201+ and PRAME+ melanoma but not ALL cell lines.
  • Quantitative real-time reverse transcription-PCR showed significantly lower PRAME mRNA levels in ALL than in melanoma cell lines, suggesting that PRAME expression in ALL is below the recognition threshold of our PRA(100-108)-tetramer+ T cells.
  • CONCLUSION: These data support the usefulness of PRAME and in particular the PRA(100-108) epitope as target for T-cell therapy of PRAME-overexpressing cancers.
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Epitopes. HLA-A Antigens / immunology. HLA-A2 Antigen. Humans. Immunotherapy / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707612.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / PRAME protein, human
  •  go-up   go-down


11. Nakamura N: A hypothesis: radiation-related leukemia is mainly attributable to the small number of people who carry pre-existing clonally expanded preleukemic cells. Radiat Res; 2005 Mar;163(3):258-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A hypothesis: radiation-related leukemia is mainly attributable to the small number of people who carry pre-existing clonally expanded preleukemic cells.
  • Human leukemia frequently involves recurrent translocations.
  • Since radiation is a well-known inducer of both leukemia and chromosomal translocations, it has long been suspected that radiation might cause leukemia by inducing specific translocations.
  • However, recent studies clearly indicate that spontaneous translocations specific to acute lymphocytic leukemia (ALL) actually occur much more frequently than do leukemia cases with the same translocations.
  • Since radiation-induced DNA damage is generated essentially randomly in the genome, it does not seem likely that radiation could ever be responsible for the induction of identical translocations of relevance to ALL in multiple cells of an individual and hence be the primary cause of radiation-related leukemia.
  • This preleukemic clone hypothesis explains various known characteristics of radiation-related ALL and implies that people who do not have substantial numbers of preleukemic cells (i.e. the great majority) are likely at low risk of developing leukemia.
  • The hypothesis can also be applied to chronic myelogenous leukemia and to young-at-exposure cases of acute myelogenous leukemia.
  • [MeSH-major] Leukemia, Radiation-Induced / etiology. Leukemia, Radiation-Induced / genetics
  • [MeSH-minor] Chromosome Aberrations. DNA Damage. Female. Humans. Male. Nuclear Warfare. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Time Factors. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733032.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


12. Abadie C, Bernard F, Netchine I, Sanlaville D, Roque A, Rossignol S, Coupier I: Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation. Eur J Med Genet; 2010 Nov-Dec;53(6):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation.
  • This syndrome is a multigenic disorder caused by dysregulation of imprinted growth regulatory genes in the 11p15.5 region.
  • We report the case of a 10-year-old patient diagnosed with BWS, harbouring a CDKN1C (p57(KIP2)) mutation, who developed a T-type acute lymphoblastic leukaemia.
  • To our knowledge it is the first report of an acute lymphoblastic leukaemia of T-type in a child with BWS.
  • We discuss the possibility of a link between BWS and leukaemia via one of the few known negative regulator of hematopoiesis, the transforming growth factor beta pathway, depending upon the up-regulation of CDKN1C.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / genetics. Cyclin-Dependent Kinase Inhibitor p57 / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20826236.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57
  •  go-up   go-down


13. Bener A, Hoffmann GF, Afify Z, Rasul K, Tewfik I: Does prolonged breastfeeding reduce the risk for childhood leukemia and lymphomas? Minerva Pediatr; 2008 Apr;60(2):155-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does prolonged breastfeeding reduce the risk for childhood leukemia and lymphomas?
  • AIM: Prolonged breastfeeding was shown to reduce the risk of childhood acute leukemia.
  • The aim of the study was to investigate the protective effect of longer breastfeeding on the risk of lymphoid malignancies in children and its dependent socio-economic factors.
  • METHODS: The study group comprised of 169 patients with acute lymphocytic leukemia (ALL), Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL), age =or<15 years, and 169 healthy controls, matched to patients by age and sex.
  • In multivariate analysis, statistically significant risk factors for the development of childhood lymphoid malignancy were: a shorter duration of breastfeeding, lower age and level of education of mother and higher income, larger size of accommodation and birth order in the family.
  • Additional factors found to be associated with an elevated risk of lymphoid malignancy were low age and low education of mother.
  • [MeSH-major] Breast Feeding. Hodgkin Disease / prevention & control. Lymphoma, Non-Hodgkin / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control

  • MedlinePlus Health Information. consumer health - Breastfeeding.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449131.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Koskenvuo M, Möttönen M, Waris M, Allander T, Salmi TT, Ruuskanen O: Human bocavirus in children with acute lymphoblastic leukemia. Eur J Pediatr; 2008 Sep;167(9):1011-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human bocavirus in children with acute lymphoblastic leukemia.
  • We report three children with acute lymphoblastic leukemia who had acute febrile episodes with concomitant detection of human bocavirus in their respiratory secretions.
  • [MeSH-major] Bocavirus / isolation & purification. Parvoviridae Infections / complications. Parvoviridae Infections / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Virol. 2007 Apr;38(4):321-5 [17336143.001]
  • [Cites] Clin Infect Dis. 2007 Apr 1;44(7):904-10 [17342639.001]
  • [Cites] J Med Virol. 2006 Mar;78(3):408-16 [16419110.001]
  • [Cites] Nat Med. 2001 Jun;7(6):719-24 [11385510.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 9;103(19):7450-3 [16651522.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1712-7 [8826932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12891-6 [16118271.001]
  • [Cites] J Infect Dis. 2006 Nov 1;194(9):1276-82 [17041854.001]
  • [Cites] Emerg Infect Dis. 2006 Sep;12(9):1457-8 [17073104.001]
  • [Cites] J Clin Microbiol. 2007 Mar;45(3):1032-4 [17215343.001]
  • [Cites] J Clin Virol. 2001 Apr;21(1):9-16 [11255093.001]
  • [Cites] Pediatr Infect Dis J. 1995 Aug;14(8):690-4 [8532427.001]
  • [Cites] J Clin Virol. 2006 Jan;35(1):99-102 [16257260.001]
  • [Cites] J Infect Dis. 2007 May 1;195(9):1345-52 [17397006.001]
  • [Cites] Emerg Infect Dis. 2004 Jun;10(6):1095-101 [15207063.001]
  • [Cites] J Clin Microbiol. 2007 Jul;45(7):2116-22 [17475762.001]
  • [Cites] Expert Rev Anti Infect Ther. 2007 Apr;5(2):245-53 [17402839.001]
  • [Cites] Emerg Infect Dis. 2006 Sep;12(9):1418-20 [17073092.001]
  • [Cites] Transfusion. 2007 Jun;47(6):1054-61 [17524097.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Dec 15;174(12):1392-9 [17008640.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):4337-9 [12409425.001]
  • [Cites] J Infect Dis. 2007 Apr 1;195(7):1038-45 [17330795.001]
  • [Cites] Emerg Infect Dis. 2006 Oct;12(10):1614-6 [17176591.001]
  • [Cites] J Clin Microbiol. 2007 Feb;45(2):610-3 [17122013.001]
  • [Cites] Clin Infect Dis. 2006 Aug 1;43(3):283-8 [16804840.001]
  • [Cites] BMC Infect Dis. 2006 Jul 11;6:109 [16834781.001]
  • [Cites] J Infect Dis. 2006 Nov 1;194(9):1283-90 [17041855.001]
  • (PMID = 18038236.001).
  • [ISSN] 1432-1076
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


15. Holleman A, den Boer ML, Cheok MH, Kazemier KM, Pei D, Downing JR, Janka-Schaub GE, Göbel U, Graubner UB, Pui CH, Evans WE, Pieters R: Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood; 2006 Sep 15;108(6):1984-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols.
  • New prognostic factors may result in better risk classification and improved treatment of children with acute lymphoblastic leukemia (ALL).
  • Recently, high expression of a gene named OPAL1 (outcome predictor in acute leukemia) was reported to be associated with favorable prognosis in ALL.
  • Therefore, we investigated whether OPAL1 expression was of prognostic importance in 2 independent cohorts of children with ALL treated on Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)-92/97 (n = 180) and St Jude Total 13 protocols (n = 257).
  • We observed a consistently higher (2.8-fold) expression of OPAL1 in TEL-AML1-positive ALL compared with TEL-AML1-negative ALL in both cohorts, but higher OPAL1 expression was not consistently associated with other favorable prognostic indicators such as age and white blood cell count, or ALL genetic subtype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Base Sequence. Child. Cohort Studies. DNA, Neoplasm / genetics. Disease-Free Survival. Female. Gene Expression. Humans. Male. Oligonucleotide Array Sequence Analysis. Prognosis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hematol. 1999 Dec;70(4):268-77 [10643153.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2234-9 [11187914.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):55-61 [11333300.001]
  • [Cites] Lancet Oncol. 2001 Oct;2(10):597-607 [11902549.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):409-17 [11905735.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2743-7 [12433682.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:102-31 [14633779.001]
  • [Cites] Trends Genet. 2004 Jun;20(6):268-72 [15145580.001]
  • [Cites] Hematol J. 2004;5 Suppl 3:S138-43 [15190296.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1229-35 [15305188.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Lancet. 1991 Aug 17;338(8764):399-403 [1678081.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1047-52 [7981053.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2403-6 [8708735.001]
  • [Cites] Blood. 1998 Jul 1;92(1):259-66 [9639525.001]
  • [Cites] Blood. 2006 Jan 15;107(2):769-76 [16189266.001]
  • (PMID = 16709928.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC1895531
  •  go-up   go-down


16. Fotiadou M, Barlow JH, Powell LA, Langton H: Optimism and psychological well-being among parents of children with cancer: an exploratory study. Psychooncology; 2008 Apr;17(4):401-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adaptation, Psychological. Adolescent. Adult. Brain Neoplasms / psychology. Brain Neoplasms / therapy. Child. Child, Preschool. Family Relations. Female. Great Britain. Humans. Infant. Leukemia, Myeloid, Acute / psychology. Leukemia, Myeloid, Acute / therapy. Male. Middle Aged. Personal Satisfaction. Personality Inventory. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Quality of Life / psychology. Social Support. Surveys and Questionnaires


17. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G: XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer; 2010 Aug;55(2):260-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL.
  • BACKGROUND: Resistance to glucocorticoid induced apoptosis is one of the major risk factors for relapse and poor outcome in childhood acute lymphoblastic leukemia (ALL).
  • In patients with T-cell ALL, poor prednisone response was associated with increased XIAP expression (median: 2.8 in good vs. 5.8 in poor responders; P = 0.005).
  • Similarly, T-cell ALL patients suffering adverse events showed higher initial XIAP levels than patients in continuous complete remission (CCR) (median: 2.7 in patients in CCR vs. 5.6 in patients suffering adverse events; P = 0.007).
  • The association with poor in vivo glucocorticoid response and outcome in T-cell ALL suggests XIAP inhibition as a promising novel approach for the treatment of resistant ALL.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. X-Linked Inhibitor of Apoptosis Protein / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bone Marrow Cells / pathology. Bone Marrow Examination. Child. Drug Resistance. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Monocytes / pathology. Pharmacogenetics. Prognosis. RNA, Messenger / analysis. Treatment Outcome. Up-Regulation


18. Fujisawa S, Tanioka F, Matsuoka T, Ozawa T, Naito K, Kobayashi M: CD7/CD19 double-positive T-cell acute lymphoblastic leukemia. Int J Hematol; 2006 May;83(4):324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD7/CD19 double-positive T-cell acute lymphoblastic leukemia.
  • We report a rare case of T-cell acute lymphoblastic leukemia (T-ALL) with an aberrant phenotype.
  • Neither T-cell receptor gamma nor immunoglobulin heavy chain rearrangement was detected in the neck LN.
  • The patient is now under maintenance therapy in the first CR without hematopoietic cell transplantation.
  • [MeSH-major] Antigens, CD19. Antigens, CD7. Head and Neck Neoplasms / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Disease-Free Survival. Humans. Male. Middle Aged. Radiography. Remission Induction


19. Falagas ME, Rafailidis PI, Kapaskelis A, Peppas G: Pyomyositis associated with hematological malignancy: case report and review of the literature. Int J Infect Dis; 2008 Mar;12(2):120-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The case patient, a 46-year old female, had non-tropical pyomyositis of the iliopsoas and obturator muscles due to Staphylococcus aureus and underlying Hodgkin's disease.
  • Forty-four patients with pyomyositis and an associated hematological malignant disease have been reported in the literature.
  • The most common types of hematological oncology diseases found were acute lymphocytic leukemia (present in 11/44 patients (25%)) and multiple myeloma (7/44 patients (15.9%)).
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Humans. Male. Middle Aged. Multiple Myeloma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Staphylococcus aureus / isolation & purification. Treatment Outcome

  • Genetic Alliance. consumer health - Pyomyositis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17723316.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 29
  •  go-up   go-down


20. Chen BA, Zhang F, Wang Y, Zheng WL, Du J, Gao C, Ding JH, Sun YY, Cheng J, Wang J, Zhao G, Chen NN, Lu ZH: [Quantitative microarray-based DNA methylation analysis of E-cadherin gene promoter in acute leukemia]. Zhonghua Zhong Liu Za Zhi; 2007 Jan;29(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantitative microarray-based DNA methylation analysis of E-cadherin gene promoter in acute leukemia].
  • OBJECTIVE: To quantitatively detect the methylation of E-cadherin gene 5'-CpG islands in acute leukemia by microarray-based DNA analysis and to briefly discuss the role of microarry for detection of methylation in tumors.
  • Five sets of oligonucleotide probes were designed to fabricate a DNA microarray to detect the methylation changes of E-cadherin gene CpG islands in acute leukemia.
  • RESULTS: Microarray assay was successfully used to quantitatively detect methylation changes of E-cadherin gene in 5 acute leukemia samples.
  • CONCLUSION: Microarray assay may be applied as an useful tool for mapping methylation changes in multiple CpG loci and for leukemia research.
  • [MeSH-major] Cadherins / genetics. DNA Methylation. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575692.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


21. Kohli R, Xu W, Brandwein J, Minden MD, Schimmer A, Schuh AC, Lipton JH, Yee K, Messner HA, Gupta V: Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR. Bone Marrow Transplant; 2010 Jul;45(7):1256-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


22. Vancura RW, Kepes JJ, Newell KL, Ha TM, Arnold PM: Secondary intracranial neoplasms exhibiting features of astrocytoma and neuroblastoma in 2 children treated for acute lymphoblastic leukemia: report of 2 cases. Surg Neurol; 2006 May;65(5):490-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary intracranial neoplasms exhibiting features of astrocytoma and neuroblastoma in 2 children treated for acute lymphoblastic leukemia: report of 2 cases.
  • We report 2 patients who were diagnosed with pre-B-cell acute lymphoblastic leukemia and later presented with intracranial malignancies.
  • Each patient was in remission for leukemia at the time of diagnosis of the second malignancy.
  • The possible causes of the brain tumors in association with acute lymphoblastic leukemia are discussed.
  • [MeSH-major] Astrocytoma. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Neoplasms, Second Primary. Neuroblastoma. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


23. Xie XS, Wan DM, Sun H: [Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation for 8 patients with leukemia and review of the literature]. Zhonghua Zhong Liu Za Zhi; 2010 Aug;32(8):636-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation for 8 patients with leukemia and review of the literature].
  • [MeSH-major] HLA Antigens / immunology. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Haplotypes. Histocompatibility Testing. Humans. Male. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122422.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


24. Hermansen NE, Ralfkiaer EM, Kjeldsen L: [Disseminated fusariosis in a patient with acute lymphoblastic leukaemia]. Ugeskr Laeger; 2008 Sep 8;170(37):2892
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disseminated fusariosis in a patient with acute lymphoblastic leukaemia].
  • [Transliterated title] Dissemineret fusariose hos en patient med akut lymfoblastaer leukaemi.
  • We present a case of a 74-year-old woman with acute lymphoblastic leukaemia who developed a rare disseminated mould infection with Fusarium solani during induction chemotherapy.
  • [MeSH-major] Dermatomycoses / microbiology. Fusarium. Immunocompromised Host. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796288.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


25. Luczyński W, Stasiak-Barmuta A, Krawczuk-Rybak M, Malinowska I: Assessment of selected co-stimulatory, adhesion and activatory molecules and cytokines of Th(1)/Th(2) balance in acute lymphoblastic leukemia in children. Arch Immunol Ther Exp (Warsz); 2005 Jul-Aug;53(4):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of selected co-stimulatory, adhesion and activatory molecules and cytokines of Th(1)/Th(2) balance in acute lymphoblastic leukemia in children.
  • INTRODUCTION: Recent years have seen a rise in the importance of cytokine production and co-stimulatory/activatory molecule expression in the immune response in leukemia.
  • The aim of our study was to assess the function of T lymphocytes in children with acute lymphoblastic leukemia (ALL) during remission induction based on selected cytokine and co-stimulatory/activatory molecule expression.
  • MATERIAL/METHODS: The study group consisted of 50 children with ALL (B cell precursor).
  • RESULTS: At the time of diagnosis we noted higher percentages of T cells with adhesion molecule ICAM-1, activation molecule CD38 expression, and an increased population of Th(2 )cells (IL-4) compared with the control group.
  • CONCLUSIONS: The results suggest T cell activation and Th(2 )predominance at the time of diagnosis and during remission induction in ALL in children.
  • These results confirm the involvement of cellular immunity in the leukemic process and can be used in immune therapy in leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Th1 Cells / cytology. Th2 Cells / cytology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16088321.001).
  • [ISSN] 0004-069X
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD28; 0 / Cytokines; 0 / HLA-DR Antigens; 0 / Immunosuppressive Agents; 0 / Receptors, Interleukin-2; 126547-89-5 / Intercellular Adhesion Molecule-1; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma; VB0R961HZT / Prednisone
  •  go-up   go-down


26. le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, Schrauder A, Rosemann A, Irving J, Stam RW, Shultz LD, Harbott J, Jürgens H, Schrappe M, Pieters R, Vormoor J: In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell; 2008 Jul 8;14(1):47-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.
  • We examined the leukemic stem cell potential of blasts at different stages of maturation in childhood acute lymphoblastic leukemia (ALL).
  • Cells sorted using the B precursor differentiation markers CD19, CD20, and CD34 were isolated from patient samples and engrafted mice before serial transplantation into primary or subsequent (up to quaternary) recipients.
  • Sorted blast populations mirrored normal B precursor cells with transcription of a number of stage-appropriate genes.
  • These observations inform a model for leukemia-propagating stem cells in childhood ALL.


27. Williams S, MacDonald P, Hoyer JD, Barr RD, Athale UH: Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. Pediatr Blood Cancer; 2005 Jan;44(1):55-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels.
  • PROCEDURE: We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels.
  • Commercially available assay was used to measure Cb5R levels.
  • Average duration of dapsone prophylaxis prior to diagnosis was 6.6 weeks (range 3.5-10 weeks).
  • [MeSH-major] Anti-Infective Agents / adverse effects. Anti-Infective Agents / therapeutic use. Cytochrome-B(5) Reductase / pharmacology. Dapsone / adverse effects. Dapsone / therapeutic use. Methemoglobinemia / chemically induced. Methemoglobinemia / prevention & control. Pneumonia, Pneumocystis / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAPSONE .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15390276.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 8W5C518302 / Dapsone; EC 1.6.2.2 / Cytochrome-B(5) Reductase
  •  go-up   go-down


28. Kastrup IB, Worm J, Ralfkiaer E, Hokland P, Guldberg P, Grønbaek K: Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol; 2008 Jan;80(1):61-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.
  • Acquired alterations of the RFC gene have been associated with resistance to MTX in cancer cell lines and primary osteosarcomas.
  • Here, we examined RFC for mutations and promoter hypermethylation in (i) the inherently MTX-resistant lymphoma cell line (RL);.
  • (ii) 30 paired cases of acute lymphoblastic leukemia (ALL) obtained at diagnosis and at relapse after treatment with MTX; and (iii) 25 cases of diffuse large B-cell lymphoma (DLBCL) at diagnosis, none of which had been previously exposed to MTX.
  • A missense mutation affecting the 11th transmembrane domain of RFC (c.1250T>C; p.I417T) was found in one case of ALL at diagnosis.
  • In ALL, RFC promoter hypermethylation was found neither at diagnosis nor at relapse and thus is not a common cause of low levels of RFC expression associated with adverse outcome.
  • In DLBCL, genetic and epigenetic alterations of RFC were detected at diagnosis in the absence of a selective MTX pressure, suggesting that these alterations may possibly contribute to the development of lymphoma.
  • [MeSH-major] Epigenesis, Genetic. Lymphoma, Large B-Cell, Diffuse / genetics. Membrane Transport Proteins / genetics. Mutation
  • [MeSH-minor] Adolescent. Adult. Biopsy. Child. Child, Preschool. Codon, Nonsense. DNA Methylation. DNA Mutational Analysis. Drug Resistance, Neoplasm / genetics. Female. Humans. Male. Methotrexate. Middle Aged. Mutation, Missense. Point Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Promoter Regions, Genetic. Reduced Folate Carrier Protein

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Haematol. 2008 Apr;80(4):365 [18194482.001]
  • (PMID = 18028428.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / Membrane Transport Proteins; 0 / Reduced Folate Carrier Protein; 0 / SLC19A1 protein, human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


29. Barbaric D, Byth K, Dalla-Pozza L, Byrne JA: Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: clinical and sample considerations. Leuk Res; 2006 Nov;30(11):1355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: clinical and sample considerations.
  • The tumor protein D52 gene or protein is frequently overexpressed in several carcinomas, and has been identified as a B cell differentiation marker.
  • We used RT-PCR to analyse the expression of three D52-like genes in bone marrow at the time of ALL or AML diagnosis in children.
  • [MeSH-major] Leukemia, Myeloid. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Proteolipids / genetics. Vesicular Transport Proteins / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Myelin and Lymphocyte-Associated Proteolipid Proteins. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620967.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MAL2 protein, human; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / TPD52 protein, human; 0 / TPD52L1 protein, human; 0 / TPD52L2 protein, human; 0 / Vesicular Transport Proteins
  •  go-up   go-down


30. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke A, Haas R, Kobbe G: Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant; 2005 Jun;35(11):1089-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
  • The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings.
  • We retrospectively compared CSA/MTX and CSA/MMF in 93 patients (median age 35 years, range 17-59 years, male subjects 48, female subjects 45) with acute myeloid leukemia (n=33), myelodysplastic syndrome (MDS) (n=3), acute lymphoblastic leukemia (ALL) (n=20) or chronic myeloid leukemia (n=37) who received CSA/MMF (n=26) or CSA/MTX (n=67) as GVHD prophylaxis following high-dose therapy and allogeneic SCT from HLA-identical siblings.
  • No statistically significant differences were found in overall survival, relapse rate, treatment-related mortality and acute or chronic GVHD.
  • [MeSH-major] Cyclosporine / administration & dosage. Graft vs Host Disease / prevention & control. Immunosuppressive Agents / administration & dosage. Methotrexate / administration & dosage. Mycophenolic Acid / administration & dosage. Mycophenolic Acid / analogs & derivatives. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Female. HLA Antigens. Histocompatibility. Histocompatibility Testing. Humans. Leukemia / mortality. Leukemia / therapy. Living Donors. Male. Middle Aged. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Recurrence. Retrospective Studies. Siblings. Time Factors. Transplantation Conditioning. Transplantation, Homologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Bone Marrow Transplant. 2006 Jan;37(2):235-6; author reply 236-7 [16284607.001]
  • (PMID = 15821769.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


31. Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N: A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol; 2009 Dec;147(5):691-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).
  • Sirolimus has been shown to have activity against human acute lymphoblastic leukaemia at serum levels used for immunosuppression.
  • We hypothesized that the addition of sirolimus to a tacrolimus/methotrexate graft-versus-host disease (GVHD) prophylaxis regimen would decrease relapse after haematopoietic stem cell transplantation and initiated a phase I/II study to demonstrate safety, feasibility, and efficacy.
  • EFS of risk groups was 74%, 81%, 44% and 46% for CR1, IR CR2, HR CR2 and CR3+ patients respectively, and did not differ by stem cell source.
  • Cumulative incidence of acute GVHD grade II-IV and III-IV was 38% and 21% respectively, while the cumulative incidence of chronic GVHD was 32%.
  • Significant toxicities included veno-occlusive disease [seven patients (11%)], transplant-associated microangiopathy (three patients), and idiopathic pneumonitis (one patient).

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1149-55 [16195324.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1112-5 [17473063.001]
  • [Cites] Eur J Clin Invest. 2008 Jan;38(1):43-52 [18173550.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):66-70 [18307022.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):531-7 [18410895.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S39-42 [18545243.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Aug;14(8):920-6 [18640576.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2020-3 [18544682.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4425-31 [18776081.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5767-74 [19001324.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):62-71 [19147081.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):377-84 [19064980.001]
  • [Cites] JAMA. 2009 Jan 28;301(4):393-403 [19176441.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6A):3801-8 [19189667.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Blood. 2002 May 1;99(9):3151-7 [11964277.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Dec;24(9):746-50 [12468917.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2043-8 [12406916.001]
  • [Cites] Transpl Int. 2003 Mar;16(3):202-6 [12664217.001]
  • [Cites] Blood. 2003 May 15;101(10):3835-9 [12732501.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1601-5 [12730113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Bone Marrow Transplant. 2004 Sep;34(6):471-6 [15273708.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):255-67 [8420443.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Jul;11(7):551-7 [15983555.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Aug;11(8):571-5 [16041306.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1396-404 [16219577.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • (PMID = 19744131.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116660-04; United States / NCI NIH HHS / CA / R01 CA116660; United States / NCI NIH HHS / CA / CA116660-04; United States / NCI NIH HHS / CA / R01 CA102646; United States / NCI NIH HHS / CA / R01 CA102646-05; United States / NCI NIH HHS / CA / CA102646-05; United States / NCI NIH HHS / CA / CA102646; United States / NCI NIH HHS / CA / CA1116660
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS209799; NLM/ PMC2888481
  •  go-up   go-down


32. Bhatti FA, Hussain I, Ali MZ: Adult B lymphoblastic leukaemia/lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia - case report and review of literature. J Hematol Oncol; 2009;2:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult B lymphoblastic leukaemia/lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia - case report and review of literature.
  • Patients suffering from adult acute lymphoblastic leukemia are acutely ill and present most commonly with fever, pallor, bleeding, lymphadenopathy, hepatosplenomegaly and presence of lymphoblasts in the peripheral blood and bone marrow.
  • We describe a rare presentation of acute lymphoblastic leukemia, in a young adult male who had vague and minimal symptoms with mild splenomegaly.
  • The blasts were positive for common precursor B cell markers on flow cytometry.
  • The patient had a unique cytogenetic abnormality t(7;12)(q22;p13),-9, not previously described in acute lymphoblastic leukemia.
  • [MeSH-major] Eosinophilia / complications. Eosinophilia / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Dev Pathol. 2003 Nov-Dec;6(6):558-63 [15018456.001]
  • [Cites] Blood. 1973 Sep;42(3):377-84 [4516523.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):382-90 [3546615.001]
  • [Cites] Br J Haematol. 1987 Sep;67(1):25-31 [3478077.001]
  • [Cites] Acta Haematol. 1989;82(2):85-90 [2508400.001]
  • [Cites] Blood. 1990 Jul 15;76(2):285-9 [2114933.001]
  • [Cites] Pediatr Hematol Oncol. 1992 Apr-Jun;9(2):151-5 [1388044.001]
  • [Cites] Blood. 1996 May 1;87(9):3579-86 [8611680.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2459-63 [8630411.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):287-95 [9031109.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2036-41 [9058725.001]
  • [Cites] N Engl J Med. 1998 May 28;338(22):1592-600 [9603798.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3038-45 [15284118.001]
  • [Cites] Lab Hematol. 2008;14(1):7-9 [18403314.001]
  • [Cites] Chin Med J (Engl). 2008 Sep 5;121(17):1744-6 [19024110.001]
  • [Cites] Oncogene. 2000 Feb 17;19(7):906-15 [10702799.001]
  • [Cites] Ann Hematol. 2000 May;79(5):272-4 [10870483.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1050-5 [11159536.001]
  • [Cites] Leukemia. 2001 Jun;15(6):915-20 [11417477.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):191-200 [12939747.001]
  • [Cites] Br J Haematol. 2003 Dec;123(5):955-6 [14632791.001]
  • [Cites] Pediatr Dermatol. 2003 Nov-Dec;20(6):502-5 [14651570.001]
  • (PMID = 19545391.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 26
  • [Other-IDs] NLM/ PMC2706857
  •  go-up   go-down


33. Klingebiel T, Lang P, Schumm M, Koehl U, Bader P, Schwabe D, Schlegel PG, Eyrich M, Greil J, Beck JF, Niethammer D, Handgretinger R: Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. Pathol Biol (Paris); 2005 Apr;53(3):159-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Antigens, CD / blood. Antigens, CD34 / blood. Cause of Death. Child. Child, Preschool. Haploidy. Hematopoietic Stem Cell Mobilization / methods. Humans. Infant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781375.001).
  • [ISSN] 0369-8114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34
  •  go-up   go-down


34. Mkrtchyan H, Garcia Ney DR, de Ventura ES, Liehr T, Felix GR, Marques-Salles Tde J, Abdelhay E, Macedo Silva ML: Molecular cytogenetic studies characterize a near-triploid complex karyotype in a child with acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2010 Feb;197(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic studies characterize a near-triploid complex karyotype in a child with acute lymphoblastic leukemia.
  • High hyperdiploidy with modal chromosome numbers between 50 and 65 is common in childhood acute lymphoblastic leukemia (ALL), occurring in 25-30% of the cases.
  • [MeSH-major] Chromosome Aberrations. Polyploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20113840.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Hong KP, Kang SH, Lee KM, Ji GY, Yoon SS, Kim JS, Son BR, Lee DG, Lee OJ, Song HG: Characterization of a Novel Monoclonal Antibody (27H2) Recognizing Human CD34 Class III Epitope. Immune Netw; 2010 Dec;10(6):239-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Monoclonal antibodies (mAbs) recognizing Class III epitope of CD34 are essential for flow cytometric diagnosis of leukemia.
  • METHODS: 27H2 mAb was developed from a mouse alternatively immunized with human acute leukemia cell lines, KG1 and Molm-1.
  • Using flow cytometric analysis of various leukemic cell lines and peripheral blood, immunohistochemical study of frozen tonsil, we characterized 27H2 mAb.
  • A case of bone marrow sample of acute lymphoblastic leukemia (ALL) patient was obtained at CBNU Hospital.
  • For epitope identification enzyme treatment with neuraminidase and O-sialoglycoprotein endopeptidase (OSGE) and blocking assay with known classIII mAb (HPCA-2) were done.
  • CD34 positive leukemic cells in BM of pre B cell ALL patient detected by FITC-conjugated 27H2 and HPCA-2 were identified with similar sensitivity.
  • CONCLUSION: A novel murine mAb recognizing class III epitope of human CD34 with high affinity, which is useful for flow cytometric diagnosis of leukemia, was developed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Mar 15;93(6):1858-68 [10068658.001]
  • [Cites] J Immunol Methods. 1997 May 26;204(2):175-88 [9212835.001]
  • [Cites] J Hematother. 1992 Summer;1(2):115-29 [1285404.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):597-605 [8826880.001]
  • [Cites] Hematol Cell Ther. 1998 Dec;40(6):259-68 [9924925.001]
  • [Cites] Leukemia. 1992;6 Suppl 1:31-6 [1372379.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Haematologica. 1991 Jul-Aug;76(4):330-3 [1724439.001]
  • [Cites] Leukemia. 1987 May;1(5):417-26 [2444831.001]
  • [Cites] Leuk Res. 1985;9(1):1-9 [3857402.001]
  • [Cites] Leuk Res. 1985;9(2):191-8 [3857408.001]
  • [Cites] Am J Pathol. 1985 Apr;119(1):1-4 [3885751.001]
  • [Cites] J Immunol. 1984 Jul;133(1):157-65 [6586833.001]
  • [Cites] Leuk Lymphoma. 1995;18 Suppl 1:25-30 [7496351.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):28-36 [7505806.001]
  • [Cites] Bone Marrow Transplant. 1995 Oct;16(4):611-6 [8528180.001]
  • [Cites] Ann N Y Acad Sci. 1995 Dec 29;770:91-8 [8597386.001]
  • [Cites] Cytometry. 1996 Jun 15;26(2):154-60 [8817092.001]
  • [Cites] J Hematother. 1996 Jun;5(3):213-26 [8817388.001]
  • [Cites] J Hematother. 1996 Dec;5(6):599-603 [9117248.001]
  • [Cites] J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):1-13 [11388737.001]
  • (PMID = 21286385.001).
  • [ISSN] 2092-6685
  • [Journal-full-title] Immune network
  • [ISO-abbreviation] Immune Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026944
  • [Keywords] NOTNLM ; 27H2 / CD34 / Class III epitope / Diagnosis / Leukemia / Monoclonal antibody
  •  go-up   go-down


36. Taub JW, Ge Y: Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer; 2005 Jan;44(1):33-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been recognized that chromosomal abnormalities in childhood leukemia, are linked to both leukemogenesis and segregate patients into prognostic treatment groups.
  • This is best exemplified in cases of children with Down syndrome (DS), who have significantly higher risks of developing leukemia compared to non-DS children and distinctive treatment outcomes, particularly in cases of acute myeloid leukemia (AML).
  • The high event-free survival (EFS) rates of DS AML patients and in particular, patients with megakaryocytic leukemia (AMkL), at least in part reflects an increased sensitivity to cytosine arabinoside (ara-C) secondary to increased expression of the chromosome 21-localized gene, cystathionine-beta-synthase, and potentially global mechanisms which increase the susceptibility of cells to undergo apoptosis.
  • Hyperdiploid acute lymphoblastic leukemia (ALL) cells with extra copies of chromosome 21, generate higher levels of the active methotrexate (MTX) metabolite, MTX polyglutamates.
  • Microarray technology should lead to the identification of additional gene targets linked to the treatment response of specific cytogenetic leukemia subgroups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 21. Down Syndrome / complications. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / metabolism. Antineoplastic Agents, Alkylating / therapeutic use. Child. Disease-Free Survival. Humans. Methotrexate / adverse effects. Methotrexate / metabolism. Methotrexate / therapeutic use. Prognosis

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15390307.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA92308
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 45
  •  go-up   go-down


37. Wu S, Gessner R, von Stackelberg A, Kirchner R, Henze G, Seeger K: Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence. Cancer; 2005 Mar 1;103(5):1054-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence.
  • BACKGROUND: Recent studies have shown that cytokines/cytokine receptors (C/CR) affect leukemic cell growth and survival.
  • The goal of the current study was to investigate possible correlations between gene expression patterns of C/CR in leukemic cells, clinical features, and outcome in children with acute lymphoblastic leukemia (ALL) at first disease recurrence.
  • METHODS: Between January 1997 and December 2000, bone marrow (BM) samples were collected from 68 children with first ALL recurrence at diagnosis.
  • These patients were enrolled in the ALL-REZ 95-96 disease recurrence trials of the Berlin-Frankurt-Munster study group.
  • RESULTS: In comparison with T-lineage ALL specimens, expression of IL-10, IFN-gamma, IL-15Ralpha, and Flt1 was significantly higher in B-cell precursor (BCP) ALL specimens (P <0.01).
  • [MeSH-major] Cytokines / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Cytokine / genetics
  • [MeSH-minor] Adolescent. Bone Marrow / chemistry. Cell Lineage. Child. Child, Preschool. Fluorescent Antibody Technique. Gene Expression. Humans. Infant. Male. Neoplasm Recurrence, Local. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome


38. Timuragaoglu A, Dizlek S, Uysalgil N, Tosun O, Yamac K: Methylenetetrahydrofolate reductase C677T polymorphism in adult patients with lymphoproliferative disorders and its effect on chemotherapy. Ann Hematol; 2006 Dec;85(12):863-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because folate is the cornerstone in DNA synthesis, we analysed herein if the polymorphisms in MTHFR gene can alter the susceptibility of lymphoproliferative disease risk and if it has an effect on chemotherapy response.
  • One hundred fifty-six patients with lymphoid malignancies and 82 healthy controls were included into the study.
  • Neither gene frequencies nor allel frequencies were found to increase lymphoproliferative disease risk significantly in both overall group and subgroups.
  • Although it was not statistically significant, we found a 2.7-fold increased risk in acute lymphocytic leukaemia (ALL)/Burkitt lymphoma patients with TT genotype [odds ratio (OR), 2.7; 95% confidence interval (CI), 0.88-8.2] than CC genotype but a 1.7-fold decreased risk with TT genotype in diffuse large B-cell lymphoma (DLBCL; OR, 0.58; 95% CI, 0.17-1.88) and a 1.8-fold decreased risk in Hodgkin's lymphoma with TT genotype (OR, 0.55; 95% CI, 0.10-2.87) than CC genotype.
  • The chemotherapy response was analysed in DLBCL, Hodgkin's lymphoma and ALL/Burkitt's lymphoma because these patients received standard chemotherapy protocols.
  • As a conclusion, MTHFR C677T polymorphism does not increase the risk of lymphoproliferative disease, and it does not have an effect on chemotherapy response significantly; however, the patients with TT genotype have a slightly increased risk for ALL, and they also respond worse than CC genotype.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Female. Genetic Predisposition to Disease. Genotype. Hodgkin Disease / drug therapy. Hodgkin Disease / genetics. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / genetics. Male. Middle Aged. Risk. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Hematol. 2007 May;86(5):389 [17211521.001]
  • (PMID = 16944145.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


39. McDonald LR, McCarthy CH: Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children. Clin J Oncol Nurs; 2006 Dec;10(6):809-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children.
  • Each year, almost 3500 children are diagnosed with leukemia, representing approximately 30% of pediatric cancer cases.
  • Acute lymphoblastic leukemia is the most common form of pediatric leukemia, accounting for approximately 80% of cases.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Arabinonucleosides / therapeutic use. Oncology Nursing / organization & administration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / nursing

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17193947.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  • [Number-of-references] 30
  •  go-up   go-down


40. Wang W, Wang HY, Zhao HX, Cui ZG, Li GL: [Expression of CD133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun;15(3):470-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CD133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome].
  • To explore the relationship between the expression of CD133 and pathogenesis of leukemia and MDS, immunocytochemistry method was used to examine the expression of CD133 in bone marrow cells of patients with leukemia and MDS.
  • The results showed that the positive rate of CD133 in 41 acute leukemia patients was 51.2%.
  • The expression of CD133 in all leukemia cells with CD34(+) was higher than that in leukemia cells with CD34(-), and there was significant difference in expression of CD133 between them (P < 0.05).
  • The high expression of CD133 may be an adverse prognostic factor in acute leukemia.


41. Li VC, Li CK: [Optimal central nervous system directed therapy in childhood acute lymphoblastic leukemia.]. Zhonghua Er Ke Za Zhi; 2007 May;45(5):339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optimal central nervous system directed therapy in childhood acute lymphoblastic leukemia.].
  • [MeSH-major] Central Nervous System / pathology. Central Nervous System Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697618.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


42. Dictor M, Warenholt J, György C, Månsson I, Larsson G: Clonal evolution to histiocytic sarcoma with the BCR/ABL rearrangement 14 years after acute lymphoblastic leukemia. Leuk Lymphoma; 2009 Nov;50(11):1892-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal evolution to histiocytic sarcoma with the BCR/ABL rearrangement 14 years after acute lymphoblastic leukemia.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Histiocytic Sarcoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883318.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Variable Region; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


43. Zaliova M, Fronkova E, Krejcikova K, Muzikova K, Mejstrikova E, Stary J, Trka J, Zuna J: Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring. Leukemia; 2009 May;23(5):944-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring.
  • Minimal residual disease (MRD) monitoring is an essential tool for risk group stratification in current treatment protocols for childhood acute lymphoblastic leukaemia (ALL).
  • Although quantitative detection of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is currently considered to be the standard method, leukaemia fusion genes provide other possible targets for MRD follow-up, as already demonstrated in TEL/AML1-positive ALLs.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Neoplasm Recurrence, Local / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Cells, Cultured. Child. Child, Preschool. Female. Gene Rearrangement, T-Lymphocyte / genetics. Genes, Immunoglobulin / genetics. Humans. Male. Neoplasm, Residual / genetics. Precursor Cells, B-Lymphoid / metabolism. Precursor Cells, B-Lymphoid / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19158828.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


44. Crazzolara R, Bradstock KF, Bendall LJ: RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy; 2009 Jul;5(5):727-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia.
  • The elimination of tumor cells by apoptosis is the main mechanism of action of chemotherapeutic drugs used in current treatment protocols of acute lymphoblastic leukemia (ALL).
  • Despite the rapid cytoreduction achieved, serious acute and late complications are frequent, and resistance to chemotherapy develops.
  • During the past decade, new strategies to kill cancer cells by nonapoptotic mechanisms have flourished and many mediators of alternate cell death pathways have been identified.
  • The discovery of alternative pathways involved in cell death execution and the role that it plays in leukemia suggest mTOR inhibitors should be included in future chemotherapy protocols of ALL.
  • [MeSH-major] Autophagy / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Sirolimus / analogs & derivatives
  • [MeSH-minor] Animals. Cell Line, Tumor. Everolimus. Humans. Mice. Tumor Burden / drug effects


45. Chen-Deutsch X, Garay E, Zhang J, Harrison JS, Studzinski GP: c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D. Leuk Res; 2009 Oct;33(10):1372-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin D.
  • 1,25-Dihydroxyvitamin D3 (1,25D) induces differentiation of myeloid leukemia cells, but resistant cells are also encountered.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Apr 4;21(15):2441-5 [11948429.001]
  • [Cites] Int J Hematol. 2002 Jun;75(5):473-83 [12095146.001]
  • [Cites] Acta Biochim Pol. 2002;49(2):393-406 [12362981.001]
  • [Cites] Cell Cycle. 2002 Nov-Dec;1(6):410-5 [12548017.001]
  • [Cites] J Cell Biochem. 2003 Aug 15;89(6):1087-101 [12898508.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):370-7 [14729647.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2004;14(1-2):1-41 [15104525.001]
  • [Cites] Mol Cell. 2004 Sep 10;15(5):713-25 [15350216.001]
  • [Cites] Nucleic Acids Res. 1991 May 11;19(9):2499 [2041787.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3451-5 [2054784.001]
  • [Cites] J Biol Chem. 1995 Feb 24;270(8):3642-7 [7876102.001]
  • [Cites] Exp Cell Res. 1996 May 1;224(2):312-22 [8612708.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2760-70 [8654373.001]
  • [Cites] Steroids. 1999 Jan-Feb;64(1-2):137-42 [10323682.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):47298-310 [15331595.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10844-56 [15572687.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):816-25 [17520689.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):736-41 [19221487.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1520-3 [15611655.001]
  • [Cites] J Cell Physiol. 2005 Sep;204(3):964-74 [15799027.001]
  • [Cites] Mol Cell. 2005 Aug 5;19(3):309-20 [16061178.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1812-7 [16107889.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):447-51 [16479173.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4402-9 [16618766.001]
  • [Cites] J Cell Biochem. 2006 Jun 1;98(3):590-617 [16440327.001]
  • [Cites] Exp Cell Res. 2006 Jul 1;312(11):2054-65 [16624284.001]
  • [Cites] Curr Top Med Chem. 2006;6(12):1267-71 [16848740.001]
  • [Cites] J Cell Physiol. 2006 Nov;209(2):253-60 [16883571.001]
  • [Cites] Mol Cell. 2006 Sep 15;23(6):899-911 [16973441.001]
  • [Cites] Expert Opin Ther Targets. 2006 Oct;10(5):735-48 [16981830.001]
  • [Cites] Biochem Soc Trans. 2006 Dec;34(Pt 6):1287-90 [17073803.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Dec;7(12):885-96 [17139329.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):54-64 [17074809.001]
  • [Cites] J Biol Chem. 2007 Mar 23;282(12):8695-703 [17242406.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1583-94 [10587349.001]
  • [Cites] Cell Mol Life Sci. 1999 Oct 30;56(5-6):538-42 [11212303.001]
  • [Cites] J Cell Biochem. 2001;80(4):471-82 [11169731.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1A):499-504 [11299787.001]
  • [Cites] Mol Cell Endocrinol. 2001 May 25;177(1-2):161-71 [11377831.001]
  • [Cites] J Cell Biochem. 2001 Apr 2-27;82(1):68-77 [11400164.001]
  • [CommentIn] Leuk Res. 2009 Oct;33(10):1298-300 [19428105.001]
  • (PMID = 19339050.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA117942-02; United States / NCI NIH HHS / CA / R01 CA044722-18A2; United States / NCI NIH HHS / CA / CA044722-18A2; United States / NCI NIH HHS / CA / R01-CA 117942-2; United States / NCI NIH HHS / CA / R01 CA117942; United States / NCI NIH HHS / CA / CA117942-02; United States / NCI NIH HHS / CA / R01 CA044722; United States / NCI NIH HHS / CA / R01-CA 044722-18
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; 0 / Antioxidants; 0 / Diterpenes, Abietane; 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / Plant Extracts; 0 / Proto-Oncogene Proteins c-jun; 0 / Pyridines; 0 / RNA, Small Interfering; 0 / Transcription Factor AP-1; 5688UTC01R / Tretinoin; EC 2.7.1.24 / Mitogen-Activated Protein Kinase 9; LI791SXT24 / salvin
  • [Other-IDs] NLM/ NIHMS102548; NLM/ PMC2706390
  •  go-up   go-down


46. Rozanov S, Keren O, Karni A: The specificity of memory for a highly trained finger movement sequence: Change the ending, change all. Brain Res; 2010 May 17;1331:80-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The specificity of memory for a highly trained finger movement sequence: Change the ending, change all.
  • How are highly trained movement sequences represented in long-term memory?
  • Here we show that the gains attained in the performance of a well-trained sequence of finger movements can be expressed only when the order of the movements is exactly as practiced.
  • Ten young adults were trained to perform a given 5-element sequence of finger-to-thumb opposition movements with their left hand.
  • Movements were analyzed using video based tracking.
  • Three weeks of training resulted, along with improved accuracy, in robustly shortened movement times as well as shorter finger-to-thumb touch times.
  • However, there was little transfer of these gains in speed to the execution of the same component movements arranged in a new order.
  • Moreover, even when the only change was the omission of the one before final movement of the trained sequence (Omit sequence), the initial movements of the sequence were significantly slowed down, although these movements were identical to the initial movements of the trained sequence.
  • Our results support the notion that a well-trained sequence of finger movements can be represented, in the adult motor system, as a singular, co-articulated, unit of movement, in which even the initial component movements are contingent on the subsequent, anticipated, ones.
  • Because of co-articulation related anticipatory effects, gains in fluency and accuracy acquired in training on a specific movement sequence cannot be expressed in full in the execution of the trained component movements or of a full segment of the trained sequence, if followed by a different ending segment.
  • [MeSH-major] Memory / physiology. Motor Skills / physiology
  • [MeSH-minor] Adult. Female. Fingers / innervation. Fingers / physiology. Humans. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier B.V.
  • (PMID = 20298683.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


47. Gahn B, Schub N, Repp R, Gramatzki M: Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation. Eur J Med Res; 2007 Aug 16;12(8):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.
  • The patient with T-cell acute lymphoblastic leukemia of thymic differentiation achieved remission after treatment according to the German ALL protocol 07/03.
  • Two months after the consolidation therapy relapse occurred requiring high dose chemotherapy with allogeneic stem cell transplantation.
  • Mycotic sepsis at the start of myeloablative conditioning therapy in heavily pretreated acute leukemia patients is usually considered as not allowing successful allogeneic transplantation.
  • Thus this case demonstrates, that allogeneic stem cell transplantation is feasible in patients presenting with systemic candidiasis if combined antifungal therapy with liposomal amphotericin B, caspofungin and voriconazole is given.
  • [MeSH-major] Antifungal Agents / therapeutic use. Bone Marrow Transplantation. Candidiasis / therapy. Hematopoietic Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adult. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Therapy, Combination. Echinocandins. Humans. Immunocompromised Host. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / therapy. Liposomes. Male. Peptides, Cyclic / therapeutic use. Pyrimidines / therapeutic use. Transplantation, Homologous. Triazoles / therapeutic use. Voriconazole

  • Genetic Alliance. consumer health - Systemic candidiasis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933709.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Liposomes; 0 / Peptides, Cyclic; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


48. Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N: A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res; 2010 Jun 1;70(11):4346-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias.
  • B-lineage acute lymphoblastic leukemia (ALL) arises by transformation of a progenitor (pre-B) cell.
  • B-cell-activating factor (BAFF) and its receptor BAFF-R are important for survival and growth of mature normal and malignant B cells but are not expressed on pre-B cells.
  • Unexpectedly, all cells in the primary Philadelphia chromosome (Ph)-positive and Ph-negative ALL samples tested were positive for high BAFF-R cell surface expression.
  • Recombinant BAFF supported survival of the ALL cells in the absence of stroma, and it significantly attenuated the rate of apoptosis caused by exposure to nilotinib, a drug used therapeutically to treat Ph-positive ALLs.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Immunity. 2006 Sep;25(3):403-15 [16973390.001]
  • [Cites] Immunology. 2006 Jul;118(3):281-92 [16827889.001]
  • [Cites] Ann Rheum Dis. 2007 Jun;66(6):790-7 [17185325.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1249-57 [17410186.001]
  • [Cites] Leukemia. 2000 Mar;14(3):399-402 [10720133.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):137-43 [10880535.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1322-30 [10903733.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1614-20 [10995008.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2111-4 [11509691.001]
  • [Cites] Br J Haematol. 2007 Aug;138(3):338-48 [17614820.001]
  • [Cites] Blood. 2007 Dec 1;110(12):3959-67 [17687108.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Cell Biochem Biophys. 2009;53(1):1-16 [19034695.001]
  • [Cites] Clin Ther. 2008 Nov;30(11):1956-75 [19108785.001]
  • [Cites] Nat Rev Immunol. 2009 Jul;9(7):491-502 [19521398.001]
  • [Cites] J Leukoc Biol. 2009 Aug;86(2):349-59 [19406831.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):665-74 [19693095.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2108-11 [11509692.001]
  • [Cites] Nat Rev Immunol. 2002 Jul;2(7):465-75 [12094221.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • [Cites] Nat Immunol. 2002 Oct;3(10):958-65 [12352969.001]
  • [Cites] Immunity. 2002 Oct;17(4):515-24 [12387744.001]
  • [Cites] Annu Rev Immunol. 2003;21:231-64 [12427767.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3268-79 [14978135.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3148-57 [15070697.001]
  • [Cites] Immunity. 2004 Apr;20(4):441-53 [15084273.001]
  • [Cites] Trends Immunol. 2004 Jun;25(6):280-8 [15145317.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):807-17 [15240667.001]
  • [Cites] Leuk Lymphoma. 2004 Jun;45(6):1181-4 [15359998.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2247-53 [15251985.001]
  • [Cites] J Exp Med. 1978 Dec 1;148(6):1570-8 [309923.001]
  • [Cites] Exp Hematol. 1985 Aug;13(7):664-9 [3861327.001]
  • [Cites] Eur J Immunol. 1989 Feb;19(2):347-56 [2784769.001]
  • [Cites] Blood. 1992 May 1;79(9):2370-7 [1373973.001]
  • [Cites] Blood. 1994 Feb 1;83(3):758-66 [7507732.001]
  • [Cites] Br J Haematol. 1996 Jan;92(1):97-103 [8562418.001]
  • [Cites] Leuk Lymphoma. 1995 Jun;18(1-2):1-16 [8580810.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] J Exp Med. 1998 Jan 19;187(2):185-96 [9432976.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1747-56 [10359578.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3290-8 [15833862.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1113-9 [16226112.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5387-93 [16707466.001]
  • [Cites] Immunity. 2006 Jun;24(6):729-39 [16782029.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1313-5 [16617317.001]
  • [Cites] Blood. 2007 Jan 15;109(2):703-10 [16973958.001]
  • (PMID = 20460528.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] None / None / / R01 CA090321-08S1; United States / NCI NIH HHS / CA / R01 CA090321-08S1; United States / NCI NIH HHS / CA / R21 CA152497-02; None / None / / R01 CA137060-01A1; United States / NCI NIH HHS / CA / R01 CA090321; United States / NCI NIH HHS / CA / R01CA090321; United States / NCI NIH HHS / CA / R21 CA152497; United States / NCI NIH HHS / CA / R01 CA090321-08; None / None / / R01 CA137060-02; None / None / / R01 CA090321-08; None / None / / R01 CA139032-01; None / None / / R01 CA137060-03; United States / NCI NIH HHS / CA / R01CA137060; United States / NCI NIH HHS / CA / R01 CA139032-02; None / None / / R01 CA139032-02; United States / NCI NIH HHS / CA / R01 CA139032-01; United States / NCI NIH HHS / CA / R01 CA090321-07; United States / NCI NIH HHS / CA / R21 CA152497-01; United States / NCI NIH HHS / CA / R01 CA137060-02; United States / NCI NIH HHS / CA / R01 CA137060-01A1; None / None / / R01 CA090321-07; None / None / / R21 CA152497-01; United States / NCI NIH HHS / CA / R01 CA139032; None / None / / R01 CA139032-03; None / None / / R21 CA152497-02; United States / NCI NIH HHS / CA / R01CA139032; United States / NCI NIH HHS / CA / R01 CA139032-03; United States / NCI NIH HHS / CA / R01 CA137060; United States / NCI NIH HHS / CA / R01 CA137060-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell Activating Factor; 0 / B-Cell Activation Factor Receptor; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / TNFRSF13C protein, human
  • [Other-IDs] NLM/ NIHMS192821; NLM/ PMC2880197
  •  go-up   go-down


49. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. Leuk Lymphoma; 2007 Oct;48(10):1922-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intravenous clofarabine showed significant efficacy in pediatric leukemias (specifically, acute lymphoblastic leukemia (ALL)) and, in 2004, it was approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric relapsed/refractory ALL after at least two regimens.
  • In adults, clofarabine has shown significant efficacy in hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) alone and in combinations.
  • [MeSH-minor] Aged. Animals. Child. Clinical Trials as Topic. DNA Damage. Drug Approval. Humans. Leukemia, Myeloid, Acute / drug therapy. Middle Aged. Models, Biological. Models, Chemical. Myelodysplastic Syndromes / drug therapy. Prognosis. Purines / chemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852710.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57629
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 0 / Purines; 762RDY0Y2H / clofarabine
  • [Number-of-references] 37
  •  go-up   go-down


50. ASBMT Executive Committee: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of acute lymphoblastic leukemia in children. Biol Blood Marrow Transplant; 2006 Mar;12(3):370-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of acute lymphoblastic leukemia in children.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503508.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Guideline; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Marwaha RK, Kulkarni KP, Bansal D, Trehan A: Pattern of mortality in childhood acute lymphoblastic leukemia: experience from a single center in northern India. J Pediatr Hematol Oncol; 2010 Jul;32(5):366-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of mortality in childhood acute lymphoblastic leukemia: experience from a single center in northern India.
  • The outcome of acute lymphoblastic leukemia (ALL) in developing countries is inferior compared with the resource-rich nations.
  • The factors associated with an increased risk of death were longer symptom diagnosis interval (P=0.049), bulk disease (P=0.008), mediastinal adenopathy (P=0.001), higher total leukocyte count (P=0.001), and lower platelet count (P=0.007) at presentation as compared with the survivors.
  • Multivariate analysis showed that longer symptom diagnosis interval (P=0.001), mediastinal adenopathy (P=0.006), lower platelet count (P=0.001), and higher total leukocyte count significantly influenced death.
  • [MeSH-major] Mortality / trends. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality


52. Heng JL, Chen YC, Quah TC, Liu TC, Yeoh AE: Dedicated cytogenetics factor is critical for improving karyotyping results for childhood leukaemias - experience in the National University Hospital, Singapore 1989-2006. Ann Acad Med Singapore; 2010 Feb;39(2):102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedicated cytogenetics factor is critical for improving karyotyping results for childhood leukaemias - experience in the National University Hospital, Singapore 1989-2006.
  • INTRODUCTION: Childhood leukaemia accounts for more than 40% of new childhood cancer cases.
  • Unfortunately, karyotyping of childhood leukaemia is difficult, laborious and often unsuccessful.
  • Among them, 369 newly diagnosed and relapsed childhood acute leukaemia cases [281 acute lymphoblastic leukaemia (ALL) and 88 acute myeloid leukaemia (AML)] have been diagnosed at NUH.
  • [MeSH-major] Cytogenetic Analysis / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20237730.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


53. Ikawa Y, Saikawa Y, Horisawa T, Kuroda R: Pancreatic and renal involvement in pediatric acute lymphoblastic leukemia/lymphoma. J Clin Oncol; 2007 Feb 1;25(4):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic and renal involvement in pediatric acute lymphoblastic leukemia/lymphoma.
  • [MeSH-major] Kidney Neoplasms / pathology. Pancreatic Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


54. Lauten M, Fernandez-Munoz I, Gerdes K, von Neuhoff N, Welte K, Schlegelberger B, Schrappe M, Beger C: Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer; 2009 Apr;52(4):459-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of the in vivo expression of glucocorticoid receptor splice variants during prednisone treatment in childhood acute lymphoblastic leukaemia.
  • BACKGROUND: The in vivo glucocorticoid response in childhood acute lymphoblastic leukaemia (ALL) correlates with the response to multi-agent chemotherapy.
  • CONCLUSIONS: Differential regulation of the cGR and its splice variants under glucocorticoid treatment rather than the expression level at diagnosis is associated with glucocorticoid response.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Gene Expression / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prednisone / therapeutic use. Receptors, Glucocorticoid / biosynthesis

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 19061214.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Protein Isoforms; 0 / Receptors, Glucocorticoid; VB0R961HZT / Prednisone
  •  go-up   go-down


55. Oshima K, Kanda Y, Yamashita T, Takahashi S, Mori T, Nakaseko C, Fujimaki K, Yokota A, Fujisawa S, Matsushima T, Fujita H, Sakura T, Okamoto S, Maruta A, Sakamaki H, Kanto Study Group for Cell Therapy: Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant; 2008 Oct;14(10):1100-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation.
  • Little information is available regarding central nervous system (CNS) relapse of adult leukemia after allogeneic hematopoietic stem cell transplantation (HSCT).
  • Therefore, we reviewed the data of 1226 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML) who received first allogeneic HSCT between 1994 and 2004, using the database of the Kanto Study Group for Cell Therapy (KSGCT), and analyzed the incidence, risk factors, and outcome of patients with CNS relapse.
  • Independent significant factors associated with CNS relapse included ALL as the underlying diagnosis (relative risk [RR] = 9.55, 95% confidence interval [CI] = 1.26-72.2, P = .029), nonremission at HSCT (RR = 2.30, 95% CI = 1.03-5.15, P = .042), the history of CNS invasion before HSCT (RR = 5.62, 95% CI = 2.62-12.0, P = 9.2 x 10(-6)), and the prophylactic intrathecal chemotherapy after HSCT (RR = 2.57, 95% CI = 1.21-5.46, P = .014).
  • In 7 of 29 patients with CNS relapse, leukemia was observed only in CNS.
  • Although the outcome of patients with CNS relapse was generally poor, long-term disease-free survival could be achieved in some patients.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Hematopoietic Stem Cell Transplantation. Leukemia / pathology. Leukemia / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Incidence. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Leukemia, Myeloid, Acute. Leukemic Infiltration. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Recurrence. Retrospective Studies. Risk Factors. Survival Rate. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804039.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Gao YJ, Lu FJ, Wang HS: Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children's hospital in China. J Pediatr Hematol Oncol; 2006 Dec;28(12):798-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children's hospital in China.
  • PURPOSE: To assess the outcome of children with acute lymphoblastic leukemia (ALL) treating with ALL China-98 in a single children's Hospital in China.
  • The patients were >or=1 and <or=15 years of age at diagnosis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. China. Developed Countries. Developing Countries. Disease-Free Survival. Female. Follow-Up Studies. Hospitals, Pediatric. Humans. Infant. Male. Recurrence. Remission Induction / methods. Retrospective Studies. Risk Factors. Sepsis / etiology. Sepsis / mortality. Survival Rate


57. Okuno K, Horie Y, Kanai K, Kato M, Kuwamoto S, Okazaki T, Hayashi K: Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia. J Clin Exp Hematop; 2009 May;49(1):45-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia.
  • Post-transplant lymphoproliferative disorder (PTLD) is one of the most important complications of solid organ transplantation or hematopoietic stem cell transplantation.
  • Although post-transplant Hodgkin lymphoma (HL) is included in PTLD, there have been no studies in the literature on adult cases of post-transplant HL after cord blood stem cell transplantation (CBSCT).
  • We report a 26-year-old woman case of post-transplant HL, which occurred after CBSCT for relapsed acute lymphoblastic leukemia.
  • Differential diagnosis of post-transplant HL with good prognosis and HL-like PTLD with aggressive behavior is important, and immunohistochemical methods were useful and essential for it.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Hodgkin Disease / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Diagnosis, Differential. Epstein-Barr Virus Infections / etiology. Female. Herpesvirus 4, Human. Humans. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Treatment Outcome. Young Adult


58. Kulkarni KP, Arya LS: Infantile acute lymphoblastic leukemia and nephromegaly. Indian J Pediatr; 2010 Oct;77(10):1199-200; author reply 1201-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile acute lymphoblastic leukemia and nephromegaly.
  • [MeSH-major] Kidney / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Indian J Pediatr. 2010 May;77(5):583 [20140762.001]
  • [Cites] Indian J Pediatr. 2010 May;77(5):583 [20140762.001]
  • [Cites] Pediatr Nephrol. 2005 May;20(5):679-82 [15714312.001]
  • [Cites] Leuk Lymphoma. 2010 Feb;51(2):261-8 [20038226.001]
  • [Cites] Leuk Res. 2010 Apr;34(4):483-6 [19631984.001]
  • [Cites] Acta Haematol. 1995;94(2):84-9 [7484018.001]
  • [Cites] Clin Lymphoma Myeloma. 2009;9 Suppl 3:S222-30 [19778845.001]
  • (PMID = 20936381.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] India
  •  go-up   go-down


59. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadié M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC, GOELAMS and GEIL study: Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol; 2009 Jun;145(5):624-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.
  • The diagnosis of plasmacytoid dendritic cell leukaemia (pDCL) is based on the immunophenotypic profile: CD4(+) CD56(+) lineage(neg) CD45RA(+)/RO(neg) CD11c(neg) CD116(low) CD123(+) CD34(neg) CD36(+) HLA-DR(+).
  • This study aimed to validate pDCL-specific markers for diagnosis by flow-cytometry or quantitative reverse transcription polymerase chain reaction on bone marrow samples.
  • Expression of markers previously found in normal pDC was analysed in 16 pDCL, four pDCL presenting an atypical phenotype (apDCL) and 113 non-pDC - lymphoid or myeloid - acute leukaemia.
  • BDCA-2 was expressed on 12/16 pDCL and on 2/4 apDCL, but was never detected in the 113 non-pDC acute leukaemia cases.
  • BDCA-4 expression was found on 13/16 pDCL, but also in 12% of non-pDC acute leukaemia.
  • High levels of LILRA4 and TCL1A transcripts distinguished pDCL and apDCL from all other acute leukaemia (except B-cell acute lymphoblastic leukaemia for TCL1A).
  • We thus propose a diagnosis strategy, scoring first the CD4(+) CD56(+/-) MPO(neg) cCD3(neg) cCD79a(neg) CD11c(neg) profile and then the CD123(high), BDCA-2 and BDCA-4 expression.
  • Atypical pDCL can be also identified this way and non-pDC acute leukaemia excluded: this scoring strategy is useful for diagnosing pDCL and apDCL.
  • [MeSH-major] Algorithms. Dendritic Cells / immunology. Leukemia / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Child. Female. Flow Cytometry / methods. Humans. Interleukin-3 Receptor alpha Subunit / analysis. Lectins, C-Type / analysis. Leukemia, Myeloid, Acute / immunology. Male. Membrane Glycoproteins / analysis. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Proto-Oncogene Proteins / analysis. Receptors, Immunologic / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388928.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CLEC4C protein, human; 0 / Interleukin-3 Receptor alpha Subunit; 0 / LILRA4 protein, human; 0 / Lectins, C-Type; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Immunologic; 0 / TCL1A protein, human
  •  go-up   go-down


60. Tse WW, Zang SL, Bunting KD, Laughlin MJ: Umbilical cord blood transplantation in adult myeloid leukemia. Bone Marrow Transplant; 2008 Mar;41(5):465-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbilical cord blood transplantation in adult myeloid leukemia.
  • Allogeneic hematopoietic stem cell (HSC) transplantation is a life-saving procedure for hematopoietic malignancies, marrow failure syndromes and hereditary immunodeficiency disorders.
  • The clinical experience of using UCB transplantation to treat pediatric acute leukemias has already shown that higher-level HLA-mismatched UCB can be equally as good as or even better than matched HSC.
  • Recently, large registries and multiple single institutional studies conclusively demonstrated that UCB is an acceptable source of HSCs for adult acute leukemia patients who lack HLA-matched donors.
  • These studies will impact the future clinical allogeneic stem cell transplantation for acute myeloid leukemia (AML), which is the most common acute leukemia in adults.
  • UCB has unique advantages of easy procurement, absence of risk to donors, low risk of transmitting infections, immediate availability, greater tolerance of HLA disparity and lower-than-expected incidence of severe graft-versus-host disease.
  • Clinical studies are needed with focus on disease-specific UCB transplantation outcomes, including AML, acute lymphoblastic leukemia, and lymphoma.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods


61. Dohda T, Maljukova A, Liu L, Heyman M, Grandér D, Brodin D, Sangfelt O, Lendahl U: Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. Exp Cell Res; 2007 Aug 15;313(14):3141-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines.
  • In T-cell acute lymphoblastic leukemia (T-ALL) NOTCH 1 receptors are frequently mutated.
  • This leads to aberrantly high Notch signaling, but how this translates into deregulated cell cycle control and the transformed cell type is poorly understood.
  • Notch activity, measured immediately downstream of the NOTCH 1 receptor, is high, but expression of the canonical downstream Notch response genes HES 1 and HEY 2 is low both in primary cells from T-ALL patients and in T-ALL cell lines.
  • We show that in T-ALL cell lines, recruitment of NOTCH 1 intracellular domain (ICD) to the SKP2 promoter was accompanied by high SKP2 and low p27Kip1 protein levels.
  • T-ALL cells show a rapid G1-S cell cycle transition, while blocked Notch signaling resulted in G0/G1 cell cycle arrest, also observed by transfection of p27Kip1 or, to a smaller extent, a dominant negative SKP2 allele.
  • Collectively, our data suggest that the aberrantly high Notch signaling in T-ALL maintains SKP2 at a high level and reduces p27Kip1, leading to more rapid cell cycle progression.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptor, Notch1 / metabolism. S-Phase Kinase-Associated Proteins / metabolism. Signal Transduction / physiology. T-Lymphocytes / metabolism
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / genetics. Basic Helix-Loop-Helix Transcription Factors / metabolism. Cell Cycle / physiology. Cell Cycle Proteins / genetics. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Child. Cyclin-Dependent Kinase Inhibitor p27. Gene Expression Profiling. Humans. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. Repressor Proteins / genetics. Repressor Proteins / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560996.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / HEY1 protein, human; 0 / HEY2 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 0 / Repressor Proteins; 0 / S-Phase Kinase-Associated Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


62. Kanazawa T, Ogawa C, Taketani T, Taki T, Hayashi Y, Morikawa A: TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease. Leuk Lymphoma; 2005 Dec;46(12):1833-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t(16;21)(p11;q22) and monitoring of minimal residual disease.
  • This study reports a 1-year-old boy with precursor B cell acute lymphoblastic leukemia (ALL) carrying t(16;21)(p11;q22).
  • Complete remission (CR) was achieved by chemotherapy oriented for acute myeloid leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Neoplasm, Residual / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA-Binding Protein FUS / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263589.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA-Binding Protein FUS; 0 / TLS-ERG fusion protein, human; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; ZRP63D75JW / Idarubicin
  •  go-up   go-down


63. Disperati P, Ichim CV, Tkachuk D, Chun K, Schuh AC, Wells RA: Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology. Leuk Res; 2006 Feb;30(2):233-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.
  • Myelodysplastic syndrome (MDS) comprises a group of clonal haematopoietic disorders characterized by peripheral blood cytopenias, bone marrow hypercellularity, and abnormal blood cell differentiation.
  • Approximately 30% of cases of MDS eventually progress to acute myelogenous leukemia (AML), while progression of MDS into acute lymphoblastic leukemia (ALL) is rare.
  • We review the cancer stem cell model and its application to these disorders, and discuss the implications of the rarity of transformation of MDS to ALL for the biology of MDS and the pathogenesis of ALL.
  • [MeSH-major] Myelodysplastic Syndromes / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046234.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 60
  •  go-up   go-down


64. Qureshi A, Mitchell C, Richards S, Vora A, Goulden N: Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. Br J Haematol; 2010 May;149(3):410-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the incidence and outcome of venous thrombosis (VT) in the UK acute lymphoblastic leukaemia (ALL) 2003 trial.
  • [MeSH-minor] Adolescent. Anticoagulants / therapeutic use. Child. Child, Preschool. Feasibility Studies. Female. Heparin, Low-Molecular-Weight / therapeutic use. Humans. Infant. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prospective Studies

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201945.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130; United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Heparin, Low-Molecular-Weight; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


65. Mossner M, Hopfer O, Nowak D, Baldus CD, Neumann U, Kmetsch A, Benlasfer O, John T, Perka C, Thiel E, Hofmann WK: Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature. Exp Hematol; 2010 Aug;38(8):661-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature.
  • OBJECTIVE: Recently, the "epigenetic molecular clock hypothesis" linked increasing DNA methylation in a distinct CpG island in the cardiac-specific homeobox gene (CSX) gene to relative mitotic cell age.
  • To determine mitotic cell age in hematopoietic cells of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients, we assessed differential CSX methylation patterns in these diseases vs age-adjusted healthy controls.
  • CONCLUSIONS: Assessment of mitotic cell age by CSX methylation analysis could reveal novel insights into the distinct progression of hematologic diseases.
  • [MeSH-major] Antigens, CD34. Bone Marrow Cells / metabolism. Cell Aging. DNA, Neoplasm / metabolism. Leukemia, Myeloid, Acute / metabolism. Mitosis. Myelodysplastic Syndromes / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism


66. Rocha V, Gluckman E: Outcomes of transplantation in children with acute leukaemia. Lancet; 2007 Jun 9;369(9577):1906-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of transplantation in children with acute leukaemia.
  • [MeSH-major] Bone Marrow Transplantation / methods. Fetal Blood / transplantation. Hematopoietic Stem Cell Transplantation / methods. Histocompatibility Testing. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2007 Jun 9;369(9577):1947-54 [17560447.001]
  • (PMID = 17560429.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Gümüş H, Per H, Kumandaş S, Yikilmaz A: Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature. Neurol Sci; 2010 Apr;31(2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reversible posterior leukoencephalopathy syndrome (RPLS) is recently described disorder with typical radiological findings in the posterior regions of the cerebral hemisphere and cerebellum.
  • We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.
  • Early recognition of RPLS as complication during different diseases and therapy in childhood may facilitate precise diagnosis and appropriate treatment.
  • [MeSH-major] Posterior Leukoencephalopathy Syndrome / diagnosis
  • [MeSH-minor] Adolescent. Brain / pathology. Child. Diagnosis, Differential. Early Diagnosis. Female. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Aug;21(7):1199-206 [10954269.001]
  • [Cites] J Neurol. 2002 Jun;249(6):780-1 [12173578.001]
  • [Cites] Neurology. 1999 Apr 12;52(6):1285-8 [10214762.001]
  • [Cites] Epilepsia. 1998 Mar;39(3):295-9 [9578048.001]
  • [Cites] Stroke. 1997 May;28(5):1082-5 [9158653.001]
  • [Cites] Pediatr Radiol. 2005 Jul;35(7):722-7 [15756541.001]
  • [Cites] Pediatr Nephrol. 2001 Jul;16(7):601-3 [11465812.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):591 [9541327.001]
  • [Cites] Radiology. 2001 Jun;219(3):756-65 [11376265.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jan;271(1):79-85 [15480723.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):1038-48 [12063238.001]
  • [Cites] Pediatr Neurol. 1999 Mar;20(3):241-3 [10207937.001]
  • [Cites] Pediatr Neurol. 2006 Mar;34(3):245-7 [16504799.001]
  • [Cites] Eur J Neurol. 2006 Mar;13(3):309-10 [16618354.001]
  • [Cites] Ann Intern Med. 1995 Oct 15;123(8):598-600 [7677301.001]
  • [Cites] Intern Med J. 2005 Feb;35(2):83-90 [15705136.001]
  • [Cites] Nephrol Dial Transplant. 1989;4(12):1065-9 [2517327.001]
  • [Cites] AJR Am J Roentgenol. 1992 Aug;159(2):379-83 [1632361.001]
  • [Cites] Pediatr Infect Dis J. 2006 Jan;25(1):85-7 [16395114.001]
  • [Cites] Curr Opin Pediatr. 1999 Dec;11(6):512-8 [10590909.001]
  • [Cites] Radiology. 1991 Aug;180(2):475-8 [2068315.001]
  • [Cites] Eur J Pediatr. 2004 Dec;163(12):728-30 [15322868.001]
  • [Cites] Pediatr Neurol. 2001 May;24(5):361-4 [11516610.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):198-203 [16123992.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Jun-Jul;16(6):1344-6 [7677037.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):447-55 [18079186.001]
  • [Cites] Radiology. 2000 Nov;217(2):371-6 [11058630.001]
  • [Cites] Pediatr Nephrol. 2003 Nov;18(11):1161-6 [14505162.001]
  • [Cites] Pediatr Nephrol. 1993 Apr;7(2):194-5 [8476718.001]
  • [Cites] Neurology. 2001 Feb 13;56(3):388-91 [11171907.001]
  • [Cites] Neurology. 1998 Nov;51(5):1369-76 [9818862.001]
  • [Cites] J Comput Assist Tomogr. 2007 Jan-Feb;31(1):148-56 [17259848.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):494-500 [8559202.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Aug;99(3):222-6 [9350407.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jan;18(1):101-6 [9010526.001]
  • [Cites] Postgrad Med J. 2001 Jan;77(903):24-8 [11123390.001]
  • [Cites] Blood. 2003 Jan 15;101(2):415-9 [12393443.001]
  • [Cites] Neurology. 1997 Oct;49(4):1174-5 [9339716.001]
  • [Cites] BMJ. 1989 Nov 18;299(6710):1258-9 [2513901.001]
  • (PMID = 19809787.001).
  • [ISSN] 1590-3478
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 42
  •  go-up   go-down


68. Sterba J, Prochazka J, Ventruba J, Kren L, Valik D, Burgetova D, Mudry P, Skotakova J, Blatny J: Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia and liver failure. Pediatr Hematol Oncol; 2005 Dec;22(8):649-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia and liver failure.
  • The authors describe an adolescent girl with acute lymphoblastic leukemia (ALL) with subsequent acute liver failure, who developed an aspergillus brain abscess.
  • Her ALL remains now in complete remission 30 months from diagnosis, with no evidence of fungal infection.
  • [MeSH-major] Antifungal Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspergillosis / drug therapy. Brain Abscess / drug therapy. Liver Failure, Acute / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251170.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  •  go-up   go-down


69. Baysal BE: A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS One; 2007 May 09;2(5):e436
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia.
  • Here, I describe that succinate dehydrogenase (SDH; mitochondrial complex II) subunit B gene (SDHB) is somatically mutated at a cytidine residue in normal peripheral blood mononuclear cells (PBMCs) and T-cell acute leukemia.
  • Examination of the PBMC cell-type subsets identifies monocytes and natural killer (NK) cells as primary sources of the mutant transcript, although lesser contributions also come from B and T lymphocytes.
  • Transcript sequence analyses in leukemic cell lines derived from monocyte, NK, T and B cells indicate that the mutational mechanism targeting SDHB is operational in T-cell acute leukemia.
  • Accordingly, substantial levels (more than 3%) of the mutant SDHB transcripts are detected in five of 20 primary childhood T-cell acute lymphoblastic leukemia (T-ALL) bone marrow samples, but in none of 20 B-ALL samples.
  • In addition, distinct heterozygous SDHB missense DNA mutations are identified in Jurkat and TALL-104 cell lines which are derived from T-ALLs.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Oct 15;104(8):2224-34 [15231578.001]
  • [Cites] Hum Genet. 2003 Aug;113(3):228-37 [12811540.001]
  • [Cites] Eur J Haematol. 1999 Sep;63(3):180-91 [10485273.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10933-40 [15572694.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] BMC Med Genet. 2005;6:39 [16288654.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):415-25 [16723977.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7615-20 [16885361.001]
  • [Cites] Anal Biochem. 2007 Jan 1;360(1):84-91 [17107651.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):7-10 [17190841.001]
  • [Cites] BMC Biol. 2007;5:12 [17376234.001]
  • [Cites] J Appl Physiol (1985). 2005 Feb;98(2):715-21 [15649883.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Nat Genet. 2000 Aug;25(4):375-6 [10932175.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):38-50 [11727199.001]
  • [Cites] Annu Rev Immunol. 2002;20:165-96 [11861601.001]
  • [Cites] J Med Genet. 2002 Mar;39(3):178-83 [11897817.001]
  • [Cites] Trends Genet. 2003 Apr;19(4):207-16 [12683974.001]
  • [Cites] Annu Rev Genet. 1990;24:305-26 [2088171.001]
  • (PMID = 17487275.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA11236
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Terminator; 0 / DNA Primers; 0 / RNA, Messenger; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Other-IDs] NLM/ PMC1855983
  • [General-notes] NLM/ Original DateCompleted: 20070727
  •  go-up   go-down


70. Campana D: Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):100-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease in acute lymphoblastic leukemia.
  • In patients with acute lymphoblastic leukemia (ALL), monitoring of minimal residual disease (MRD) offers a way to precisely assess early treatment response and detect relapse.
  • Hence, results of MRD studies can be used to select treatment intensity and duration, and to estimate the optimal timing for hematopoietic stem cell transplantation.
  • Practical issues in the implementation of MRD assays in clinical studies include determining the most informative time point to study MRD and the levels of MRD that will trigger changes in treatment intensity, as well as the relative cost and informative power of different methodologies.
  • The identification of new markers of leukemia and the use of increasingly refined assays should further facilitate routine monitoring of MRD and help to clarify the cellular and biologic features of leukemic cells that resist chemotherapy in vivo.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3046-50 [18565891.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Blood. 2006 Jul 1;108(1):97-102 [16537802.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):686-94 [11849234.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1952-8 [11877265.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Haematologica. 2007 May;92(5):612-8 [17488684.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1508-16 [10735899.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):481-9 [18710378.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:366-73 [19074112.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):227-37 [18492099.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1939-43 [11069029.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):275-81 [11167819.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1485-7 [11516112.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1982-4 [11535539.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):409-17 [11905735.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1432-6 [12145681.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):849-51 [14520434.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Lancet. 1980 May 24;1(8178):1144 [6154853.001]
  • [Cites] Leuk Res. 1981;5(4-5):301-9 [7026903.001]
  • [Cites] Blood. 1988 Jul;72(1):299-307 [3291983.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(15):5698-702 [3165197.001]
  • [Cites] Leukemia. 1988 Oct;2(10):628-33 [3172839.001]
  • [Cites] Leukemia. 1989 Feb;3(2):155-8 [2536129.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):5123-7 [2500663.001]
  • [Cites] Blood. 1989 Oct;74(5):1762-7 [2676018.001]
  • [Cites] Blood. 1990 Jul 1;76(1):163-71 [1973061.001]
  • [Cites] Anal Cell Pathol. 1990 Jul;2(4):229-40 [1703434.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1289-95 [8413409.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):196-200 [7904666.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1416-34 [7888664.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] Br J Haematol. 1997 Nov;99(2):314-9 [9375747.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):139-52 [10440852.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1971-80 [15470492.001]
  • [Cites] Leukemia. 2005 Jan;19(1):49-56 [15538405.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • (PMID = 19100372.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NCI NIH HHS / CA / P30 CA021765; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  • [Other-IDs] NLM/ NIHMS89417; NLM/ PMC2632881
  •  go-up   go-down


71. Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Dürkop H, Sterry W, Eberle J: Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol; 2007 Oct;127(10):2425-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
  • Control of apoptosis via death ligands plays a basic role for lymphocyte homeostasis and lymphoma development.
  • In this study, cutaneous T-cell lymphoma (CTCL) cell lines revealed pronounced resistance to death ligands as compared to cell lines of T-cell acute lymphoblastic leukemia (T-ALL).
  • The proapoptotic activity of tumor necrosis factor (TNF)-alpha was blocked, sensitivity to TNF-related apoptosis-inducing ligand was significantly reduced, and 1/4 CTCL cell lines was resistant to CD95 activation.
  • No indication for a responsibility of typical downstream regulators of apoptosis was obtained, but loss of CD95 was found in 1/4, loss of TNF-R1 in 3/4, loss of caspase-10 in 2/4, loss of Bid in 1/4, and overexpression of cellular flice inhibitory protein was found in 4/4 CTCL cell lines.
  • [MeSH-major] Apoptosis / physiology. Lymphoma, T-Cell, Cutaneous / pathology. Receptors, Death Domain / antagonists & inhibitors. Signal Transduction / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD95 / physiology. BH3 Interacting Domain Death Agonist Protein / physiology. CASP8 and FADD-Like Apoptosis Regulating Protein / physiology. Caspase 10 / physiology. Cell Line, Tumor. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / physiopathology. Male. Middle Aged. TNF-Related Apoptosis-Inducing Ligand / antagonists & inhibitors. TNF-Related Apoptosis-Inducing Ligand / physiology. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / physiology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495957.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / BID protein, human; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / Receptors, Death Domain; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; EC 3.4.22.- / Caspase 10
  •  go-up   go-down


72. van Galen JC, Kuiper RP, van Emst L, Levers M, Tijchon E, Scheijen B, Waanders E, van Reijmersdal SV, Gilissen C, van Kessel AG, Hoogerbrugge PM, van Leeuwen FN: BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. Blood; 2010 Jun 10;115(23):4810-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia.
  • Resistance to glucocorticoids (GCs) is a major clinical problem in the treatment of acute lymphoblastic leukemia (ALL), but the underlying mechanisms are not well understood.
  • [MeSH-major] Drug Resistance, Neoplasm. Gene Expression Regulation, Leukemic. Neoplasm Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, Glucocorticoid / biosynthesis
  • [MeSH-minor] Cell Line, Tumor. Female. Gene Deletion. Glucocorticoids / adverse effects. Glucocorticoids / pharmacology. Glucocorticoids / therapeutic use. Humans. Male. Multiprotein Complexes / genetics. Multiprotein Complexes / metabolism. Promoter Regions, Genetic / genetics. Protein-Arginine N-Methyltransferases / genetics. Protein-Arginine N-Methyltransferases / metabolism. RNA Interference. Repressor Proteins / genetics. Repressor Proteins / metabolism. Transcription, Genetic / drug effects. Transcription, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354172.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Multiprotein Complexes; 0 / Neoplasm Proteins; 0 / Receptors, Glucocorticoid; 0 / Repressor Proteins; 146835-72-5 / BTG1 protein, human; EC 2.1.1.- / PRMT1 protein, human; EC 2.1.1.- / Protein-Arginine N-Methyltransferases
  •  go-up   go-down


73. Koufopantelis P, Georgakakou S, Kazanis M, Giaginis C, Margeli A, Papargiri S, Panderi I: Direct injection liquid chromatography/positive ion electrospray ionization mass spectrometric quantification of methotrexate, folinic acid, folic acid and ondansetron in human serum. J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov 15;877(30):3850-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A rapid liquid chromatography/positive ion electrospray mass spectrometric assay (LC/ESI-MS) was developed for the quantitation of methotrexate, folinic acid, folic acid and ondansetron in human serum.
  • The assay was based on 100microL serum samples, following acetonitrile precipitation of proteins and filtration that enabled direct injection into the LC/MS system.
  • The assay was found to be linear in the concentration range of 0.01-25.00microgmL(-1) for methotrexate and 0.01-5.00microgmL(-1) for folic acid, folinic acid and ondansetron.
  • The method can be used to quantify methotrexate, folinic acid, folic acid and ondansetron in human serum covering a variety of clinical studies and it was applied to the analysis of human serum samples obtained from children with acute lymphoblastic leukemia.

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19828383.001).
  • [ISSN] 1873-376X
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 4AF302ESOS / Ondansetron; 935E97BOY8 / Folic Acid; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


74. Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, Iliopoulos D, Caligiuri MA, Huebner K, Croce CM: Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res; 2006 Jun 01;12(11 Pt 1):3494-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35.
  • Adenovirus 5 (Ad5) virus or adeno-associated viral vectors have been used to study the tumor suppressor function of FHIT in solid tumors, but these tools have not been effective in leukemias.
  • EXPERIMENTAL DESIGN: Infection efficiency of Ad5/F35-FHIT and Ad5/F35-GFP viruses was tested in leukemia cell lines that lacked FHIT expression, and biological effects of successful infection were assessed.
  • An acute myelogenous leukemia, a chronic myelogenous leukemia, and four acute lymphoblastic leukemia human cell lines were examined as well as two EBV-transformed B lymphoblastoid cell lines that expressed endogenous FHIT.
  • RESULTS: Two of four acute lymphoblastic leukemia cell lines, Jurkat and MV4;11, which were efficiently infected with Ad5/F35-FHIT, underwent growth suppression and massive induction of apoptosis without apparent activation of caspase-8 or caspase-2 and late activation of caspase-3.
  • The two remaining infected acute lymphoblastic leukemia cell lines, Molt-3 and RS4;11, were apparently unaffected.
  • Restoration of FHIT expression in the chronic myelogenous leukemia K562 cell line and the acute myelogenous leukemia KG1a cell line also induced apoptosis but at later time points than seen in the acute lymphoblastic leukemia Jurkat and MV4;11 cell lines. I.v. injection of Ad5/F35-FHIT-infected Jurkat cells resulted in abrogation of tumorigenicity in the NOD/SCID xenogeneic engraftment model.
  • CONCLUSION: FHIT restoration in some FHIT-deficient leukemia cells induces both antiproliferative and proapoptotic effects involving the intrinsic caspase apoptotic pathway.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Adenoviruses, Human / genetics. Gene Expression Regulation, Neoplastic / genetics. Genetic Therapy / methods. Leukemia / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / genetics. Cell Cycle. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Drug Screening Assays, Antitumor. Enzyme Inhibitors / pharmacology. Gene Transfer Techniques. Genetic Vectors / genetics. Green Fluorescent Proteins / genetics. Humans. Kinetics. Mice. Mice, Inbred NOD. Mice, SCID. Structure-Activity Relationship. Transplantation, Heterologous. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2016 Dec 15;22(24):6304 [27856602.001]
  • (PMID = 16740775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA56036; United States / NCI NIH HHS / CA / CA77738; United States / NCI NIH HHS / CA / CA78890; United States / NCI NIH HHS / CA / CA89341
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


75. Jeon IS, Yi DY: Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus. Pediatr Hematol Oncol; 2009 Mar;26(2):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus.
  • Acute lymphoblastic leukemia (ALL), a primary hematologic malignancy that is especially common in childhood, occurs relatively rarely as a secondary malignant neoplasm.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Perivascular Epithelioid Cell Neoplasms / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Uterine Neoplasms / complications
  • [MeSH-minor] Anthracyclines / adverse effects. Child. Cytogenetic Analysis. Female. Humans. Precursor Cells, B-Lymphoid / pathology. Topoisomerase II Inhibitors. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322738.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Topoisomerase II Inhibitors
  •  go-up   go-down


76. Caudell D, Harper DP, Novak RL, Pierce RM, Slape C, Wolff L, Aplan PD: Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. Blood; 2010 Feb 11;115(6):1194-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The t(10;11) translocation results in a CALM-AF10 fusion gene in a subset of leukemia patients.
  • Expression of a CALM-AF10 transgene results in leukemia, with prolonged latency and incomplete penetrance, suggesting that additional events are necessary for leukemic transformation.
  • CALM-AF10 mice infected with the MOL4070LTR retrovirus developed acute leukemia, and ligation-mediated polymerase chain reaction was used to identify retroviral insertions at 19 common insertion sites, including Zeb2, Nf1, Mn1, Evi1, Ift57, Mpl, Plag1, Kras, Erg, Vav1, and Gata1.
  • A total of 91% (10 of 11) of mice with Zeb2 insertions developed B-lineage acute lymphoblastic leukemia, suggesting that Zeb2 activation promotes the transformation of CALM-AF10 hematopoietic precursors toward B-lineage leukemias.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Jan;14(1):93-9 [10637482.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10024-7 [19074864.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 1):S40-7 [11263664.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:179-98 [12194988.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):166-74 [12185365.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):153-9 [12185366.001]
  • [Cites] J Virol. 2003 Apr;77(8):4965-71 [12663802.001]
  • [Cites] Methods Mol Biol. 2003;220:213-33 [12744216.001]
  • [Cites] J Med Genet. 2003 May;40(5):305-10 [12746390.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1831-4 [15385933.001]
  • [Cites] J Natl Cancer Inst. 1977 Jul;59(1):93-4 [195075.001]
  • [Cites] Blood. 1987 Jul;70(1):192-9 [3496132.001]
  • [Cites] Nat Genet. 1994 Jul;7(3):353-61 [7920653.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1511-9 [7731705.001]
  • [Cites] J Virol. 1995 Aug;69(8):5095-102 [7609078.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5434-43 [7565694.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):137-43 [8563750.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4804-9 [8643484.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Nov;20(3):253-9 [9365832.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):551-4 [9407945.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3714-25 [9649441.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4210-8 [15315976.001]
  • [Cites] Blood. 2005 Jan 15;105(2):784-93 [15454493.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2183-5 [15928039.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7656-72 [16299527.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4269-77 [16105979.001]
  • [Cites] Histol Histopathol. 2006 Jul;21(7):761-74 [16598675.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1684-9 [16690971.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):363-74 [17097559.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3898-905 [16912223.001]
  • [Cites] Cell Cycle. 2007 Mar 1;6(5):550-66 [17351342.001]
  • [Cites] Hum Mutat. 2007 Apr;28(4):313-21 [17203459.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5148-55 [17545593.001]
  • [Cites] J Interferon Cytokine Res. 2007 Jul;27(7):543-52 [17651015.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12919-24 [17644613.001]
  • [Cites] PLoS One. 2007;2(8):e768 [17712416.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8022-31 [17804713.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):26-33 [17910045.001]
  • [Cites] Genes Dev. 2008 Mar 15;22(6):756-69 [18347095.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2249-52 [18413813.001]
  • [Cites] Leukemia. 2008 May;22(5):915-31 [18288131.001]
  • [Cites] Immunity. 2000 Jul;13(1):15-24 [10933391.001]
  • (PMID = 20007546.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AF10-CALM fusion protein, human; 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Repressor Proteins; 0 / Zfhx1b protein, mouse; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2826231
  •  go-up   go-down


77. Sahin F, Sercan Z, Ertan Y, Ocakci S, Ay E, Vural F, Yuksel E, Tombuloglu M, Saydam G: Rapid transformation of atypical myeloproliferative disorder with consistent t(8;13) to B-cell acute lymphoblastic leukemia: a case report. Hematology; 2007 Dec;12(6):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid transformation of atypical myeloproliferative disorder with consistent t(8;13) to B-cell acute lymphoblastic leukemia: a case report.
  • 8p11 myeloproliferative syndrome (EMS; also known as the stem cell leukemia syndrome-SCLL) is a rare atypical myeloproliferative disorder associated with chromosomal abnormalities involving the 8p11 chromosomal band.
  • Disease phenotype associated with this translocation has some typical features such as poor prognosis, and transformation to mainly acute leukemia and non-Hodgkin lymphoma; commonly with a T-cell phenotype in which obtaining and maintenance of remission is difficult by conventional chemotherapy.
  • We hereby present a case diagnosed as atypical chronic myeloproliferative disease with consistent t(8;13)(p12;q12) and transformed rapidly to pre-B-cell acute lymphoblastic leukemia which is a rare clinical presentation.
  • [MeSH-major] Burkitt Lymphoma / etiology. Cell Transformation, Neoplastic. Myeloproliferative Disorders / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852454.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Vitale A, Guarini A, Chiaretti S, Foà R: The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol; 2006 Nov;18(6):652-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing scene of adult acute lymphoblastic leukemia.
  • PURPOSE OF REVIEW: The review focuses on the most recent advances in the diagnostic and prognostic work-up of adult acute lymphoblastic leukemia (ALL) and its implications in the clinical management of the disease.
  • RECENT FINDINGS: ALL can be identified on the basis of morphologic, cytochemical and immunophenotypic criteria; modern management of ALL is also based on cytogenetic and genetic evaluations.
  • New technologies, such as gene expression profile analysis, may allow us to further unravel the intrinsic biology of the disease, to improve diagnostic and prognostic stratification, and to design innovative therapeutic strategies.
  • In potentially all cases, specific markers of the disease can be found and utilized together with the rearrangement of immunoglobulin and T-cell receptor genes to monitor minimal residual disease during clinical follow-up.
  • SUMMARY: Recent biologic advancements are progressively realising the possibility of designing targeted and individualized therapeutic strategies according to the more refined, molecularly defined features of leukemic cells and the presence or absence of residual disease in adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neoplasm, Residual / diagnosis. Neoplasm, Residual / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988590.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 104
  •  go-up   go-down


79. Nath N, Chattopadhyay M, Pospishil L, Cieciura LZ, Goswami S, Kodela R, Saavedra JE, Keefer LK, Kashfi K: JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism. Biochem Pharmacol; 2010 Dec 1;80(11):1641-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • β-Catenin is a central player of the Wnt signaling pathway that regulates cell-cell adhesion and may promote leukemia cell proliferation.
  • We examined whether JS-K, an NO-donating prodrug, modulates the Wnt/β-catenin/TCF-4 signaling pathway in Jurkat T-Acute Lymphoblastic Leukemia cells.
  • JS-K inhibited Jurkat T cell growth in a concentration and time-dependent manner.
  • The IC(50)s for cell growth inhibition were 14±0.7 and 9±1.2μM at 24 and 48h, respectively.
  • This growth inhibition was also due, in part, to alterations in the different phases of the cell cycle.
  • The β-catenin/TCF-4 transcriptional inhibitory activity was reduced by 32±8, 63±5, and 93±2% at 2, 10, and 25μM JS-K, respectively, based on luciferase reporter assays.
  • Based on a time-course assay of S-nitrosylation of proteins by a biotin switch assay, S-nitrsolyation of nuclear β-catenin was determined to precede its degradation.
  • [MeSH-major] Azo Compounds / pharmacology. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / physiology. Nitric Oxide / secretion. Piperazines / pharmacology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Prodrugs / pharmacology. Signal Transduction / physiology. Transcription Factors / physiology. beta Catenin / physiology

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20797387.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Azo Compounds; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Growth Inhibitors; 0 / Nitroso Compounds; 0 / O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate; 0 / Piperazines; 0 / Prodrugs; 0 / TCF4 protein, human; 0 / Transcription Factors; 0 / Wnt Proteins; 0 / beta Catenin; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


80. Saito T, Usui N, Asai O, Yano S, Sugiyama K, Hisatomi M, Ueda K, Dobashi N, Kobayashi M: Toxicity and outcome of intensive chemotherapy for acute lymphoblastic leukemia complicated with Turner's syndrome. Intern Med; 2005 Feb;44(2):145-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity and outcome of intensive chemotherapy for acute lymphoblastic leukemia complicated with Turner's syndrome.
  • A 17-year-old woman was diagnosed as acute lymphoblastic leukemia (ALL).
  • As she had chromosomal abnormalities of 44, XO, der(9)t(3;9)(q11;p13), der(10;19)(q10;p10), del(15)(q15), -16, -19, +22 with the presence of ovarian dysplasia and abnormal physical features, a diagnosis of Turner's syndrome was made.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Turner Syndrome / complications
  • [MeSH-minor] Adolescent. Chromosomes, Human, X / genetics. Diagnosis, Differential. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Karyotyping. Liver / drug effects. Remission Induction. Sex Chromosome Aberrations. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Turner Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750276.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Subramaniam P, Babu KL, Nagarathna J: Oral manifestations in acute lymphoblastic leukemic children under chemotherapy. J Clin Pediatr Dent; 2008;32(4):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral manifestations in acute lymphoblastic leukemic children under chemotherapy.
  • Leukemia is a common malignancy seen in young children and acute lymphoblastic leukemia (ALL) accounts for 75% of all leukemias.
  • Immune suppression caused due to disease and therapy makes these children more prone to bacterial, fungal infections and at times reactivation of viral diseases.
  • [MeSH-major] Oral Ulcer / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Stomatitis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18767465.001).
  • [ISSN] 1053-4628
  • [Journal-full-title] The Journal of clinical pediatric dentistry
  • [ISO-abbreviation] J Clin Pediatr Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


82. İrken G, Ören H, Öniz H, Çetingül N, Vergin C, Atabay B, Gülen H, Türker M, Kantar M, Yılmaz Ş: Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome. Turk J Haematol; 2006 Sep 5;23(3):142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome.
  • [Transliterated title] Çocukluk çağı akut lenfoblastik lösemisinde hiperlökositoz: komplikasyonlar, tedavi, prognoz.
  • Hyperleukocytosis, defined as a peripheral leukocyte count ≥ 100x109/L, is seen in 5-20% of newly diagnosed cases of childhood leukemia and is a poor prognostic factor.
  • In this study, we aimed to examine the presenting clinical and laboratory features, complications, and treatment outcome of 47 children with acute lymphoblastic leukemia (ALL) and hyperleukocytosis who were diagnosed and treated in four medical centers of İzmir between January 1990 and January 2001.
  • Median white blood cell count was 495x109/L (range: 107x109/L- 794x109/L).
  • Forty-two of 47 patients (90%) had hepatosplenomegaly, 5 (11%) had respiratory distress, 3 (6%) had neurologic symptoms, 3 (6%) had diffuse cervical lymphadenopathy, and 3 (6%) had acute renal failure at admission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265481.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


83. Lofstad GE, Reinfjell T, Hestad K, Diseth TH: Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only. Acta Paediatr; 2009 Jan;98(1):180-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only.
  • OBJECTIVE: To examine cognitive outcome in children and adolescents with acute lymphoblastic leukaemia (ALL) in remission, treated with central nervous system prophylactic chemotherapy only.
  • METHOD: Thirty-five children and adolescents, age 8.4-15.3 years in long-term remission from ALL, 4.2-12.4 years post diagnosis, without relapse and no pre-diagnosis history of neurodevelopmental disorder were compared with 35 healthy controls matched for gender and age, on measures of intellectual functioning Wechsler Intelligence Scale for Children-Third Edition (WISC-III).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cognition / drug effects. Cognition Disorders / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ment Retard Dev Disabil Res Rev. 2006;12(3):174-83 [17061283.001]
  • [Cites] J Pediatr Psychol. 2000 Mar;25(2):59-68 [10820944.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Feb;24(2):106-14 [11990695.001]
  • [Cites] Dev Neuropsychol. 2002;21(2):173-95 [12139198.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] Child Neuropsychol. 2004 Mar;10(1):14-23 [14977512.001]
  • [Cites] J Clin Exp Neuropsychol. 2004 Aug;26(5):684-97 [15370390.001]
  • [Cites] J Child Psychol Psychiatry. 1988 Nov;29(6):839-52 [3069852.001]
  • [Cites] Arch Dis Child. 1995 Aug;73(2):136-40 [7574857.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2490-6 [7595698.001]
  • [Cites] J Dev Behav Pediatr. 1996 Dec;17(6):392-8 [8960568.001]
  • [Cites] J Pediatr Psychol. 1997 Dec;22(6):861-70 [9494322.001]
  • [Cites] J Pediatr Psychol. 1998 Oct;23(5):333-40 [9782681.001]
  • [Cites] Arch Neurol. 1998 Dec;55(12):1561-8 [9865801.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2608-17 [9874469.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):478-86 [15918215.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Neuropsychology. 2000 Apr;14(2):189-200 [10791859.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):941-9 [16411228.001]
  • (PMID = 18826490.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2659382
  •  go-up   go-down


84. Gupta A, Al Alenezi H, Ibrahim JM, Marouf R: Acute lymphoblastic leukaemia presenting as vasculitis. Br J Haematol; 2006 Feb;132(4):384
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia presenting as vasculitis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Vasculitis / etiology

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412013.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Gavhed D, Akefeldt SO, Osterlundh G, Laurencikas E, Hjorth L, Blennow K, Rosengren L, Henter JI: Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis. Pediatr Blood Cancer; 2009 Dec 15;53(7):1264-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis.
  • BACKGROUND: Progressive neurodegeneration may result in potentially severe cognitive and motor dysfunctions as a complication of Langerhans cell histiocytosis (LCH), a suggested IL-17A-associated inflammatory condition.
  • PROCEDURE: Nine patients with endocrine, neuromotor, cognitive or/and behavioral abnormalities as well as neuroradiological evidence of CNS-LCH were evaluated 4-12 years after LCH diagnosis for CSF levels of neurofilament protein light chain (NF-L), glial fibrillary acid protein (GFAp), and total tau protein (TAU).
  • One hundred ten children with newly diagnosed acute lymphoblastic leukemia (ALL) served as controls.
  • The patient with most severe clinical and neuroradiological CNS-LCH displayed the highest levels of NF-L and GFAp whereas three patients without signs of systemic disease had low TAU levels and normal/slightly elevated NF-L.
  • It would be valuable if these markers were validated in order to serve as markers for early CNS-LCH, to monitor disease progression and to evaluate various treatment attempts for CNS-LCH.
  • [MeSH-major] Cerebrospinal Fluid Proteins / analysis. Glial Fibrillary Acidic Protein / cerebrospinal fluid. Histiocytosis, Langerhans-Cell / cerebrospinal fluid. Nerve Degeneration. Neurofilament Proteins / cerebrospinal fluid. tau Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Biomarkers. Brain / pathology. Brain / radiography. Child. Child, Preschool. Cognition Disorders / cerebrospinal fluid. Cognition Disorders / etiology. Disease Progression. Female. Follow-Up Studies. Humans. Infant. Male. Pituitary Diseases / cerebrospinal fluid. Pituitary Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid. Spinal Puncture / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688833.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cerebrospinal Fluid Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Neurofilament Proteins; 0 / neurofilament protein L; 0 / tau Proteins
  •  go-up   go-down


86. Ma X, Urayama K, Chang J, Wiemels JL, Buffler PA: Infection and pediatric acute lymphoblastic leukemia. Blood Cells Mol Dis; 2009 Mar-Apr;42(2):117-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infection and pediatric acute lymphoblastic leukemia.
  • In this review, we provide an overview of recent findings from the Northern California Childhood Leukemia Study (NCCLS) on factors related to the immune system including child's vaccination history and measures of child's exposure to infectious agents, namely daycare attendance, infection during infancy, and parental social contact in the work place.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Dec 15;152(12):1136-44 [11130619.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Cancer Causes Control. 2001 Sep;12(7):645-52 [11552712.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):732-7 [11875735.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Apr;16(2):154-65 [12060313.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):139-45 [14710221.001]
  • [Cites] Epidemiology. 2004 May;15(3):352-6 [15097020.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):915-21 [15128601.001]
  • [Cites] Am J Epidemiol. 1986 Oct;124(4):590-4 [3463201.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Leukemia. 1993 Jan;7(1):27-34 [8418376.001]
  • [Cites] J Public Health Med. 1993 Mar;15(1):9-15 [8471307.001]
  • [Cites] BMJ. 1993 Sep 25;307(6907):774 [8219951.001]
  • [Cites] J Epidemiol Community Health. 1994 Dec;48(6):601-2 [7830017.001]
  • [Cites] Br J Cancer. 1997;75(3):457-63 [9020498.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Br J Cancer. 1997;76(12):1539-45 [9413937.001]
  • [Cites] Cancer Causes Control. 1998 May;9(3):237-9 [9684703.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Occup Environ Med. 1999 Jul;56(7):438-42 [10472313.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1928-34 [16103439.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1091-7 [16184475.001]
  • [Cites] Int J Epidemiol. 2005 Oct;34(5):1100-9 [15951359.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):496-504 [17182983.001]
  • [Cites] Int J Epidemiol. 2007 Feb;36(1):110-6 [17227780.001]
  • [Cites] J Virol. 2007 Jul;81(14):7629-35 [17494079.001]
  • [Cites] Int J Epidemiol. 2007 Aug;36(4):724-30 [17255350.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1315-21 [17923868.001]
  • [Cites] Pediatr Hematol Oncol. 2007 Dec;24(8):607-13 [18092251.001]
  • [Cites] Leukemia. 2008 Jan;22(1):189-93 [17690702.001]
  • [Cites] Am J Epidemiol. 2008 Mar 1;167(5):598-606 [18079130.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):234-40 [10638995.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):1002-7 [11286484.001]
  • (PMID = 19064328.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES009137-05; United States / NIEHS NIH HHS / ES / R01 ES009137; United States / NIEHS NIH HHS / ES / R01 ES009137-05
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  • [Other-IDs] NLM/ NIHMS171758; NLM/ PMC2834409
  •  go-up   go-down


87. Gao F, Chia KS, Krantz I, Nordin P, Machin D: On the application of the von Mises distribution and angular regression methods to investigate the seasonality of disease onset. Stat Med; 2006 May 15;25(9):1593-618
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the application of the von Mises distribution and angular regression methods to investigate the seasonality of disease onset.
  • This paper describes an approach to summarize the data arising from studies investigating the pattern of disease onset within a calendar year.
  • The methodology is applied to examples from the date of onset of primary angle-closure glaucoma and date of diagnosis of acute lymphoblastic leukaemia and examines in both situations how the peak onset varies with covariates.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Glaucoma, Angle-Closure / epidemiology. Humans. Leptospirosis / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382488.001).
  • [ISSN] 0277-6715
  • [Journal-full-title] Statistics in medicine
  • [ISO-abbreviation] Stat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Newton R: Geographical variation in the incidence of acute lymphoblastic leukaemia in childhood-Is it real? Cancer Epidemiol; 2009 Dec;33(6):401-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographical variation in the incidence of acute lymphoblastic leukaemia in childhood-Is it real?
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Epidemiol. 2009 Dec;33(6):403-5 [19833572.001]
  • (PMID = 19932647.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


89. Ashford J, Schoffstall C, Reddick WE, Leone C, Laningham FH, Glass JO, Pei D, Cheng C, Pui CH, Conklin HM: Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer; 2010 Oct 1;116(19):4638-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attention and working memory abilities in children treated for acute lymphoblastic leukemia.
  • BACKGROUND: To extend investigation beyond global cognitive measures prevalent in the literature, this study examined attention and working memory (WM) abilities of survivors of childhood acute lymphoblastic leukemia (ALL), the separate contributions of attention and WM to intelligence quotient (IQ), and their association with neuroimaging changes.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] J Pediatr Psychol. 2007 Oct;32(9):1127-39 [17569711.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):941-9 [16411228.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 Nov;30(10):1947-54 [19643920.001]
  • [Cites] Am J Psychiatry. 2000 Feb;157(2):275-7 [10671401.001]
  • [Cites] Neuropsychology. 2000 Apr;14(2):189-200 [10791859.001]
  • [Cites] Biol Psychol. 2000 Oct;54(1-3):241-57 [11035225.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1802-8 [11251012.001]
  • [Cites] Magn Reson Med. 2002 May;47(5):912-20 [11979570.001]
  • [Cites] Cancer. 2003 May 15;97(10):2512-9 [12733151.001]
  • [Cites] Bull Menninger Clin. 2003 Spring;67(2):132-42 [14604098.001]
  • [Cites] Pediatr Rehabil. 2004 Jan-Mar;7(1):1-14; discussion 15-6 [14744668.001]
  • [Cites] Brain Res. 1979 Mar 16;163(2):195-205 [427544.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):49-53 [1512162.001]
  • [Cites] Ann N Y Acad Sci. 1995 Dec 15;769:85-96 [8595046.001]
  • [Cites] Cogn Psychol. 1997 Jun;33(1):5-42 [9212720.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Dec;16(6):911-8 [9533591.001]
  • [Cites] Brain Res Cogn Brain Res. 1998 Jul;7(1):1-13 [9714705.001]
  • [Cites] Arch Dis Child. 1999 Apr;80(4):318-23 [10086934.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1263-9 [15891195.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Oct;26(9):2371-7 [16219848.001]
  • [Cites] J Consult Clin Psychol. 2008 Jun;76(3):367-78 [18540731.001]
  • (PMID = 20572038.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA090246; United States / NCI NIH HHS / CA / P30 CA21765; United States / NCI NIH HHS / CA / R01 CA90246
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS212777; NLM/ PMC2946517
  •  go-up   go-down


90. Crom DB, Tyc VL, Rai SN, Deng X, Hudson MM, Booth A, Rodrigues LN, Zhang L, McCammon E, Kaste SC: Retention of survivors of acute lymphoblastic leukemia in a longitudinal study of bone mineral density. J Child Health Care; 2006 Dec;10(4):337-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retention of survivors of acute lymphoblastic leukemia in a longitudinal study of bone mineral density.
  • This study investigated the variables associated with dropout of survivors of acute lymphoblastic leukemia in a trial investigating the effect of vitamin D and calcium supplementation and nutritional counseling on bone mineral density (BMD).
  • [MeSH-major] Attitude to Health. Longitudinal Studies. Motivation. Patient Dropouts / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Survivors / psychology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101625.001).
  • [ISSN] 1367-4935
  • [Journal-full-title] Journal of child health care : for professionals working with children in the hospital and community
  • [ISO-abbreviation] J Child Health Care
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


91. Liu TB, Luo XF, Chen ZZ, Hu JD: [Effects of small interference RNA against c-myc on expression of c-myc and h-tert genes in acute lymphoblastic leukemia cell line Jurkat]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of small interference RNA against c-myc on expression of c-myc and h-tert genes in acute lymphoblastic leukemia cell line Jurkat].
  • This study was purposed to investigate the effect of small interfering RNA against c-myc on c-myc, h-tert gene and protein expressions in acute lymphoblastic leukemia cell line (Jurkat cells), so as to provide new methods and targets for gene therapy of leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129250.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Subunits; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Small Interfering; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


92. Zhang CZ, Fung MA, Eisen DB: Disseminated fusariosis presenting as panniculitis-like lesions on the legs of a neutropenic girl with acute lymphoblastic leukemia. Dermatol Online J; 2009;15(10):5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated fusariosis presenting as panniculitis-like lesions on the legs of a neutropenic girl with acute lymphoblastic leukemia.
  • In immunocompromised patients, this antifungal resistance is of particular concern because localized infection quickly becomes disseminated disease with high mortality rates.
  • We present a case of fusariosis in an 11-year-old neutropenic patient with acute lymphoblastic leukemia whose only symptom of the fungal infection consisted of painful, indurated nodules and plaques on her legs.
  • The diagnosis and treatment of this invasive fungal infection is also discussed.
  • [MeSH-major] Dermatomycoses / diagnosis. Fusarium
  • [MeSH-minor] Child. Female. Humans. Neutropenia / complications. Panniculitis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Panniculitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951623.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Kim J, Chang W, Sagong M: Bilateral serous retinal detachment as a presenting sign of acute lymphoblastic leukemia. Korean J Ophthalmol; 2010 Aug;24(4):245-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral serous retinal detachment as a presenting sign of acute lymphoblastic leukemia.
  • We present a case of bilateral serous retinal detachment (SRD) as a presenting sign of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL).
  • A diagnosis of Ph(+) ALL was made.
  • The sudden appearance of SRD should raise suspicion for leukemia.
  • Prompt recognition of this disease is important for early systemic treatment and restoration of visual function.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Retinal Detachment / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Ann Ophthalmol. 1979 Dec;11(12):1867-72 [299244.001]
  • [Cites] Surv Ophthalmol. 1983 Jan-Feb;27(4):211-32 [6342189.001]
  • [Cites] Ophthalmology. 1983 Aug;90(8):899-905 [6195573.001]
  • [Cites] Arch Ophthalmol. 1988 Jan;106(1):21-2 [3422150.001]
  • [Cites] Br J Ophthalmol. 2000 Nov;84(11):1318-9 [11203168.001]
  • [Cites] Clin Lab Haematol. 1991;13(2):217-20 [1934932.001]
  • [Cites] Acta Ophthalmol Scand. 1998 Dec;76(6):700-3 [9881556.001]
  • [Cites] Eur J Ophthalmol. 2005 Mar-Apr;15(2):284-6 [15812775.001]
  • [Cites] Clin Experiment Ophthalmol. 2006 Aug;34(6):623-5 [16925719.001]
  • [Cites] Retina. 1989;9(2):110-4 [2772418.001]
  • (PMID = 20714390.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2916108
  • [Keywords] NOTNLM ; Acute lymphoblastic leukemia / Precursor cell lymphoblastic leukemia-lymphoma / Serous retinal detachment
  •  go-up   go-down


94. Annett RD, Erickson SJ: Feasibility of a school reintegration programme for children with acute lymphoblastic leukaemia. Eur J Cancer Care (Engl); 2009 Jul;18(4):421-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of a school reintegration programme for children with acute lymphoblastic leukaemia.
  • Despite children with acute lymphoblastic leukaemia missing a significant amount of school, little empirical literature guides the optimal content, setting and timing of a school reintegration programme.
  • Eight families with children aged 6-12 years diagnosed with acute lymphoblastic leukaemia and parents were enrolled in the study.
  • Recruitment aims proved more difficult: enrolment was extended when recruitment for the original 1- to 6-month post-diagnosis window proved difficult.
  • [MeSH-major] Mainstreaming (Education) / organization & administration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / rehabilitation. Schools

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594612.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


95. O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H: Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer; 2008 Oct 15;113(8):2097-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
  • BACKGROUND: Understanding the causes of failure in older patients with acute lymphocytic leukemia (ALL) may help improve treatment strategies for patients in this particular age group.
  • The incidence of disease resistance during induction was 5%, 27%, and 2%, respectively (P < .001).
  • CONCLUSIONS: The results of the current study suggested that intensifying the chemotherapy in older patients with ALL reduced the incidence of leukemia resistance but increased the incidence of death in CR from myelosuppression-associated infections.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18720356.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ NIHMS629431; NLM/ PMC4199453
  •  go-up   go-down


96. Wang H, Wang Y: LC-MS/MS coupled with stable isotope dilution method for the quantification of 6-thioguanine and S(6)-methylthioguanine in genomic DNA of human cancer cells treated with 6-thioguanine. Anal Chem; 2010 Jul 1;82(13):5797-803
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thiopurines, including mercaptopurine (MP), 6-thioguanine ((S)G) and azathioprine, are widely used for the treatment of many human diseases including acute lymphoblastic leukemia (ALL).
  • It was proposed that S(6)mG, owing to its high miscoding potential (pairing preferentially with thymine), may induce cell death by triggering the postreplicative mismatch repair pathway.
  • Here we developed a sensitive HPLC coupled with tandem mass spectrometry (LC-MS/MS) method and measured the level of 6-thio-2'-deoxyguanosine ((S)dG) and S(6)mdG in genomic DNA of four human leukemia cell lines and one human colorectal carcinoma cell line.
  • However, only less than 0.02% of (S)dG was converted to S(6)mdG in the above cell lines.

  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • [Cites] Biochemistry. 2009 Mar 17;48(10):2290-9 [19236003.001]
  • [Cites] Clin Chem. 2002 Jan;48(1):61-8 [11751539.001]
  • [Cites] J Clin Invest. 2003 Apr;111(8):1133-45 [12697733.001]
  • [Cites] Exp Cell Res. 1981 Oct;135(2):465-8 [7198047.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3665-71 [6204746.001]
  • [Cites] Science. 1989 Apr 7;244(4900):41-7 [2649979.001]
  • [Cites] Biochem Pharmacol. 1990 Sep 1;40(5):1063-9 [2390103.001]
  • [Cites] Mutagenesis. 1991 May;6(3):175-7 [1881347.001]
  • [Cites] J Pediatr. 1991 Dec;119(6):985-9 [1960624.001]
  • [Cites] Lancet. 1993 Feb 13;341(8842):436 [8094196.001]
  • [Cites] Lancet. 1993 May 1;341(8853):1151 [8097831.001]
  • [Cites] Biochemistry. 1994 Apr 26;33(16):4787-93 [8161538.001]
  • [Cites] Leuk Res. 1994 Nov;18(11):805-10 [7967706.001]
  • [Cites] J Chromatogr B Biomed Appl. 1995 Oct 6;672(1):53-61 [8590937.001]
  • [Cites] Science. 1996 Aug 23;273(5278):1109-11 [8688098.001]
  • [Cites] Pharmacogenetics. 1996 Aug;6(4):279-90 [8873214.001]
  • [Cites] Biochemistry. 1997 Mar 4;36(9):2501-6 [9054555.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 1998 Jan 23;705(1):29-37 [9498667.001]
  • [Cites] Eur J Clin Pharmacol. 1998 May;54(3):265-71 [9681671.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Blood. 1953 Nov;8(11):965-99 [13105700.001]
  • [Cites] N Engl J Med. 1963 Jun 13;268:1315-23 [13936775.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1871-4 [16166520.001]
  • [Cites] Clin Chem. 2005 Nov;51(11):2074-84 [16166171.001]
  • [Cites] J Biol Chem. 2008 Aug 29;283(35):23665-70 [18591241.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Mar;47(3):199-205 [11320662.001]
  • (PMID = 20550170.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK082779-01A1; United States / NCI NIH HHS / CA / R56 CA096906-06A2; United States / NCI NIH HHS / CA / R56 CA96906; United States / NIDDK NIH HHS / DK / R01 DK082779-01A1; United States / NCI NIH HHS / CA / CA096906-06A2; United States / NIDDK NIH HHS / DK / R01 DK082779; United States / NCI NIH HHS / CA / R56 CA096906
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Nitrogen Isotopes; 1198-47-6 / 6-methylthioguanine; FTK8U1GZNX / Thioguanine
  • [Other-IDs] NLM/ NIHMS214547; NLM/ PMC2922690
  •  go-up   go-down


97. Speleman F, De Preter K, Hoebeeck J, Van Roy N, Vandesompele J: [New insights into the genetic basis of neuroblastoma]. Verh K Acad Geneeskd Belg; 2007;69(4):167-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Nieuwe inzichten in de genetische basis van neuroblastoom.
  • Neuroblastoma (NB) is, next to acute lymphoblastic leukaemia, brain tumours and lymphoma the most frequent paediatric tumour (8-10%).
  • A second important part of our work focussed on the gene expression profiling of NB precursor cells.
  • Gene expression analyses of model systems developed in our lab and of a large panel of cell lines and tumours allowed us to subtract a list of candidate genes which are now under further study.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17821957.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


98. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood; 2007 Apr 15;109(8):3214-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
  • Central nervous system (CNS) prophylaxis has led to a significant improvement in the outcome of patients with acute lymphocytic leukemia (ALL).
  • Liposomal cytarabine 50 mg was given intrathecally on days 2 and 15 of hyper-CVAD and day 10 of high-dose MTX and cytarabine courses until completion of either 3, 6, or 10 IT treatments, depending on risk for CNS disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemic Infiltration / prevention & control. Meninges. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2007 Sep 1;110(5):1698; author reply 1698-9 [17712051.001]
  • (PMID = 17209054.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


99. Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, Van Lunzen J, Stellbrink HJ, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst HA: AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma; 2006 Sep;47(9):1872-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
  • The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen.
  • Group A received a protocol which was adapted from the German multi-center study group for adult acute lymphoblastic leukemia (GMALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065000.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; CHOP protocol
  •  go-up   go-down


100. Campana D: Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am; 2009 Oct;23(5):1083-98, vii
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.
  • Assays that measure minimal residual disease (MRD) can determine the response to treatment in patients with acute lymphoblastic leukemia (ALL) much more precisely than morphologic screening of bone marrow smears.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3046-50 [18565891.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:366-73 [19074112.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2193-200 [18754029.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):100-6 [19100372.001]
  • [Cites] JAMA. 2009 Jan 28;301(4):393-403 [19176441.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4153-62 [19141862.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1073-9 [19212338.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3533-9 [19546402.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):227-37 [18492099.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] Leukemia. 2000 Jun;14(6):1143-52 [10865981.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1208-14 [10914544.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1939-43 [11069029.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):275-81 [11167819.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1485-7 [11516112.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1982-4 [11535539.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):686-94 [11849234.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1952-8 [11877265.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Lancet Oncol. 2001 Oct;2(10):597-607 [11902549.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):409-17 [11905735.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1971-80 [15470492.001]
  • [Cites] Leukemia. 2005 Jan;19(1):49-56 [15538405.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1432-6 [12145681.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):849-51 [14520434.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Br Med J. 1966 Mar 12;1(5488):640-2 [5218168.001]
  • [Cites] Blood. 1980 Sep;56(3):430-41 [6996767.001]
  • [Cites] Leuk Res. 1981;5(4-5):301-9 [7026903.001]
  • [Cites] Blood. 1987 Oct;70(4):1073-8 [3477296.001]
  • [Cites] Blood. 1988 Jul;72(1):299-307 [3291983.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(15):5698-702 [3165197.001]
  • [Cites] Leukemia. 1988 Oct;2(10):628-33 [3172839.001]
  • [Cites] Leukemia. 1989 Feb;3(2):155-8 [2536129.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):5123-7 [2500663.001]
  • [Cites] Blood. 1989 Oct;74(5):1762-7 [2676018.001]
  • [Cites] Blood. 1990 Jul 1;76(1):163-71 [1973061.001]
  • [Cites] Anal Cell Pathol. 1990 Jul;2(4):229-40 [1703434.001]
  • [Cites] Clin Chim Acta. 1991 Apr;198(1-2):93-174 [1863986.001]
  • [Cites] Leukemia. 1991 Aug;5(8):657-67 [1909409.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6061-5 [8327485.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3063-74 [8219197.001]
  • [Cites] Leukemia. 1993 Dec;7(12):2045-53 [7902888.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):196-200 [7904666.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3930-7 [7579363.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] Br J Haematol. 1997 Nov;99(2):314-9 [9375747.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3774-81 [9850021.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Leukemia. 1999 Feb;13(2):196-205 [10025893.001]
  • [Cites] Leukemia. 1999 Mar;13(3):419-27 [10086733.001]
  • [Cites] Curr Top Microbiol Immunol. 1999;246:205-13; discussion 214-5 [10396058.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):139-52 [10440852.001]
  • [Cites] Leukemia. 1999 Aug;13(8):1221-6 [10450750.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Blood. 2006 Jul 1;108(1):97-102 [16537802.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Haematologica. 2007 May;92(5):612-8 [17488684.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4022-9 [17720883.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • (PMID = 19825454.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA60419; United States / NCI NIH HHS / CA / P30 CA021765; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  • [Other-IDs] NLM/ NIHMS132490; NLM/ PMC2762949
  •  go-up   go-down






Advertisement